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ABSTRACT 
 
One of the largest obstacles in drug development is to overcome solubility 
and bioavailability problems.  Preformulation strategies such as nanoparticle 
formation are often employed but sometimes create new issues and are limited in 
their effectiveness and applications.  Since the majority of drugs are marketed 
and sold as solid forms, drug delivery systems are not always desirable.  This is 
where solid-state chemistry becomes important.  Traditional solid-state chemistry 
approaches are often successful but are sometimes too restrictive and cannot be 
applied to certain compounds.  Cocrystals have emerged as an alternative solid-
state technique that can be applied to a broad range of compounds.  However, 
the technology is still very new and its effectiveness in certain conditions had 
previously not been evaluated. 
The studies detailed herein investigated the ability of two different 
technology platforms for overcoming drug design challenges for two promising 
bioflavonoids: EGCg and quercetin.  Studies have shown that EGCg might be 
useful for the treatment of Alzheimer’s disease and other neurodegenerative 
diseases.  Quercetin is being investigated for numerous bioactivities and is 
currently being marketed as an energy dietary supplement.  Both of these 
bioflavonoids exhibit poor bioavailability and water solubilities that are at opposite 
ends of the spectrum.  In the chapters to follow, nanoparticle technology was 
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applied to EGCg and evaluated in cell models of Aβ production, a hallmark of 
Alzheimer’s disease.  Bioavailability improvements were also evaluated in rats.  
Additionally, new forms of both flavonoids were created using cocrystallization.  
These new cocrystals were characterized using powder and single crystal x-ray 
diffraction, differential scanning calorimetry, and thermogravimetric analysis.  
Solubility and bioavailability changes were also evaluated.  These data have 
strong implications in drug development since they elucidated the strengths and 
weaknesses of two major technologies in compounds with different design 
challenges.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Bioflavonoids 
Bioflavonoids are a group of polyphenolic compounds that are common 
throughout the plant kingdom.  They are widely studied and have been found to 
promote healthy living in epidemiologic studies (Hertog 1996; Arts 2008).  Much 
of the attention that bioflavonoids have attracted is due mainly to the “French 
paradox”.  This is the dietary anomaly in which people in the Mediterranean 
culture have a higher fat intake but a lower incidence of cardiovascular disease 
and increased longevity (Formica and Regelson 1995).  This phenomenon has 
been largely attributed to increased dietary intake in bioflavonoids.   
1.2 (-)-Epigallocatechin-3-Gallate 
1.2.1 EGCg Therapeutic Properties 
EGCg has been studied extensively during the last decade for it’s therapeutic 
potential in various cancers (Jung, Kim et al. 2001; Wang and Bachrach 2002; 
Hwang, Ha et al. 2007; Lim, Park et al. 2008; Wang, Hao et al. 2009), 
Alzheimer’s disease (Rezai-Zadeh, Shytle et al. 2005; Obregon, Rezai-Zadeh et 
al. 2006; Rezai-Zadeh, Arendash et al. 2008; Lin, Chen et al. 2009), obesity 
(Hwang, Park et al. 2005; Wolfram 2007), and diabetes (Lin and Lin 2008; Cai 
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and Lin 2009).  In the chapters to come the focus will be on EGCg’s potential as 
an Alzheimer’s disease therapeutic.  Therapies that oppose cleavage of amyloid 
precursor protein (APP) into Aβ peptides and resultant cerebral amyloidosis, a 
key pathological feature of Alzheimer's disease (AD), have become a primary 
focus in the recent years.  The main targets have been β- and γ-secretase, the 
two proteases that cleave APP at the amino and carboxyl-terminus of the Aβ 
peptide, respectively, and hence are directly responsible for Aβ peptide 
generation.  However, numerous studies have shown that γ-secretases critically 
involve physiologically important signaling mechanisms required for cell-fate 
decisions during development and even during adulthood (De Strooper, Annaert 
et al. 1999; Walsh, Fadeeva et al. 2003).  Most recently, it has been reported that 
β-secretase modulates myelination in the central and peripheral nervous system 
(Hu, Hicks et al. 2006).  An alternative strategy, namely the activation of α-
secretase, has scarcely been investigated for its therapeutic potential.  α-
secretase cleaves APP substrate within the Aβ peptide domain and precludes 
peptide generation, thereby promoting the non-amyloidogenic pathway of APP 
proteolysis.  α-secretase activation may even have the added advantage of, not 
only preventing neurotoxic Aβ peptide formation, but also generating the 
putatively neuroprotective sAPP-α.  Recently, we found that oral administration of 
green tea-EGCg reduces β-amyloid mediated cognitive impairment, reduces 
inflammation, and also modulates tau pathology in an Alzheimer's disease 
transgenic mouse model (Rezai-Zadeh, Shytle et al. 2005; Arendash, Schleif et 
al. 2006; Obregon, Rezai-Zadeh et al. 2006; Rezai-Zadeh, Arendash et al. 2008).  
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For these reasons, EGCg was selected as one of the bioflavonoids for the 
studies to be discussed in the chapters to come.  
1.2.2 EGCg Metabolism 
The metabolism of EGCg has been identified as a major factor contributing to its 
low oral bioavailability.  For this reason, EGCg metabolism has been studied in 
mice, rats, and humans.  Because rats are most commonly used for preclinical 
bioavailability studies, there have been numerous studies on the absorption and 
metabolism of EGCg in rats (Chen, Lee et al. 1997; Nakagawa and Miyazawa 
1997).  Rats are typically the preferred species for bioavailability studies because 
they offer the logistical advantage of being more tolerant to the volumes of blood 
that must be withdrawn in order to generate a pharmacokinetic curve for each 
rat.  In mice, multiple animals must be sacrificed to generate data for each time 
point.  However, recent data suggests that mice may metabolize polyphenols in a 
manner that more closely resembles human metabolism from a mechanistic 
perspective (Lu, Meng et al. 2003).  EGCg metabolism was studied in the 
presence of mice, rat, and human UDP-glucuronosyl-transferase.  The 
investigators reported that mice and humans had a more similar EGCg 
metabolite profile than rats and humans (Lu, Meng et al. 2003).  This is 
evidenced by the presence of similar levels of (-)-EGCg-4"-O-glucuronide and (-)-
EGCg-3"-O-glucuronide in mice and in humans.  In additional experiments, 
Lambert and colleagues reported that the rat liver cytosol had a substantially 
higher capacity for methylating and sulfating EGCg than mice or human liver 
cytosol (Lambert, Lee et al. 2003).  This would account for the previously 
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reported lower bioavailabilities reported for rats, 1.6 ± 0.6% than for mice, 26.5 ± 
7.5% (Lambert, Lee et al. 2003).  In mice and in humans, EGCg is reported to be 
extensively glucoronidated by UDP-glucuronosyl-transferase, which is present at 
high levels in the intestine and liver (Lambert, Lee et al. 2003; Lu, Meng et al. 
2003). This metabolic conjugation reduces the levels of free EGCg in systemic 
circulation for transport to the target organs.  Because higher levels of free EGCg 
have been observed in mice than in humans, it would seem that UDP-
glucuronosyltransferases may not be as effective at metabolizing EGCg as 
sulfotransferases and methyltransferases in rats or is more easily saturated.  
Nonetheless, EGCg preformulation studies where metabolism is a targeted 
parameter for improving the pharmacokinetics should use a mouse model, as it is 
probably most relevant for translation in humans.  Recently, a clinical trial was 
conducted to assess whether or not long term EGCg supplementation would 
modulate the cytochrome P450 (CYP) system in man, an essential system for 
drug metabolism.  They reported that EGCg had no effects on CYP1A2, 
CYP2D6, and CYP2C9, but had very small effects on CYP3A4 activity (Chow, 
Hakim et al. 2006).  Chow and colleagues concluded that it is unlikely that long 
term EGCg administration will have any clinically relevant metabolic drug 
interactions for drugs metabolized by the CYP isozymes.  Because EGCg 
seemed to have no effect on CYP activity, one might also conclude that these 
enzymes are likely not to blame for the low bioavailability of EGCg.  However, 
this presumption is yet to be determined directly.  
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1.2.3 EGCg Biodistribution 
Many studies with animal models have shown that EGCg can prevent 
carcinogenesis of the skin, lung, oral cavity, esophagus, intestine, colon, prostate 
(Yang, Maliakal et al. 2002) and exert neuroprotective effects in the central 
nervous system (Xie, Jiang et al. ; Lee, Bae et al. 2004; Giunta, Obregon et al. 
2006; Avramovich-Tirosh, Reznichenko et al. 2007; Hou, Chen et al. 2008; 
Rezai-Zadeh, Arendash et al. 2008).  Therefore, one can infer that EGCg must 
reach these target organs.  Several groups have studied the distribution of tea 
catechins following oral consumption (Chen, Lee et al. 1997; Nakagawa and 
Miyazawa 1997; Lambert, Lee et al. 2003; Lin, Wang et al. 2007).  Lambert et al 
reported that after intravenous administration of 21.8umol/kg of EGCg in mice, 
most was distributed to the lung, liver, kidney, small intestine and colon. 
However, when the EGCg was given per oral dose of 163.8umol/kg, very large 
quantities of EGCg could be measured in the small intestine and in the colon 
(Lambert, Lee et al. 2003). This confirms that EGCg is poorly absorbed in the 
small intestine and could also be due to substantial metabolic conjugation of the 
EGCg that is absorbed before it reaches systemic circulation, leading to it’s rapid 
elimination before being distributed to the organs.  One of the newest proposed 
therapeutic uses of EGCg is that it might offer some neuroprotective properties.  
However, for a compound to have direct effects on the central nervous system, it 
should cross the blood brain barrier.  Nakagawa measured tissue distribution of 
500mg/kg EGCg 60 minutes after oral administration in rats.  EGCg 
concentration was highest in the small intestine (565 nmol/g) and colon (68.6 
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nmol/g), but was also measured in the liver (48.3 nmol/g) and in the brain (0.5 
nmol/g) (Nakagawa and Miyazawa 1997).  These results indicated that although 
EGCg can penetrate the blood brain barrier, it does so poorly.  Lin et al proposed 
that this might be due to EGCg’s bipolar functional group and the possiblility that 
EGCg is largely protein-bound in the plasma and that the complex might be too 
large to traverse cells or capillary membranes in the brain (Lin, Wang et al. 
2007).  Thus, this is an important limitation that will need to be overcome or 
compensated for by substantial increases in the systemic absorption of EGCg in 
order for it to be therapeutically effective in the cerebrospinal compartment.   
1.3 Quercetin 
Quercetin, 3,3',4',5,7-Pentahydroxyflavone, (QUE) is one of the most common 
dietary flavonoids and is found throughout the plant kingdom.  A typical Western 
diet was estimated to provide between 0 and 30 mg of QUE per day, most of 
which is consumed as tea, red wine, fruits and vegetables (Egert, Wolffram et al. 
2008).  This not only supports its safety for consumption by humans (albeit at a 
low dose), but also provides epidemiological evidence for its beneficial effects.   
1.3.1 Quercetin Therapeutic Properties 
Quercetin is best known for its antioxidant activity but has numerous other 
biological and pharmacological effects including metal chelation, anti-
carcinogenic, cardioprotective, bacteriostatic, and antiviral activity (Vargas and 
Burd ; Bakay, Mucsi et al. 1968; Formica and Regelson 1995; Spencer, Kuhnle 
et al. 2003; Leopoldini, Russo et al. 2006; Murakami, Ashida et al. 2008).   
 
	   	  7	  
1.4 Lipid Carriers 
Self-assembled polymer micelles based on amphiphilic block copolymers have 
attracted substantial interest as delivery vehicles particularly for anti-cancer 
drugs (Yokoyama, Fukushima et al. 1998; Bontha, Kabanov et al. 2006; Liu, Lee 
et al. 2006; Tian, Bromberg et al. 2007; Huynh, Passirani et al. 2009; Kim, 
Kabanov et al. 2009; Siddiqui, Adhami et al. 2009).  Additionally, lipid carriers 
with incorporated drugs have been demonstrated to increase the absorption and 
circulation time in the body versus stand-alone compounds secondary to 
minimized renal clearance (Maeda 2001; Huynh, Passirani et al. 2009).  
Liposomes have been shown to increase the permeability of tea catechins, 
including EGCg, in a mouse model of basal cell carcinoma (Fang, Lee et al. 
2006).  However, this study involved intratumor injection and, therefore, did not 
address the issue of oral bioavailability.   
1.5 Cocrystals 
Formulation of pharmaceutical ingredients is a fundamental process in drug 
development.  Isolation of crystal forms of active pharmaceutical ingredients 
(API) is paramount in the industry in order to obtain pure forms.  However, in 
many cases the crystalline API has less than favorable physicochemical 
characteristics.  For this reason, a new branch of formulation is growing in 
popularity, crystal engineering.  Crystal engineering can be used to create new 
multi-component crystalline solids coined cocrystals.  Shan and Zaworotko have 
defined cocrystals as “multiple component crystals in which all components are 
solid under ambient conditions.  These components co-exist as a stoichiometric 
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ratio of a target molecule or ion and a neutral molecular cocrystal former(s)” 
(Shan and Zaworotko 2008).  Cocrystals are of growing interest because often 
various cocrystals can be formed that improve the physicochemical properties 
(e.g. solubility and stability), improve efficacy (e.g. bioavailability), and provide 
means for extending the life cycle of old APIs (Yadav, Shete et al. 2009).  In a 
recent study, cocrystallization was used to improve the dissolution profile of a 
Class II BCS compound (low solubility, high permeability) such that it’s water 
solubility was 18 times greater, which translated into plasma concentration 
values that were three fold higher in dogs following oral administration 
(McNamara, Childs et al. 2006).  These findings lend promise to the use of 
cocrystallization for improving APIs and could even prevent potentially useful 
compounds from being ignored due to poor clinical efficacy.   
  
	   	  9	  
 
 
 
 
 
CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Reagents and Materials 
Green tea-derived EGCg (>95% purity by HPLC) was purchased from 
www.herbs-tech.com.  Quercetin dihydrate (98% purity), Isonicotinamide (INM) 
(99% purity), Caffeine (CAF), and Theobromine (TBR) (98% purity) were 
purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).  The BCA 
protein assay kit was purchased from Pierce Biotechnology (Rockford, IL, USA).  
Anti-human amyloid-βჼantibodies 4G8 and 6E10 were obtained from Signet 
Laboratories (Dedham, MA, USA) and Biosource International (Camarillo, CA, 
USA), respectively. 
2.2 Cell Models 
2.2.1 SweAPP N2a cells; APP695 
Murine neuroblastoma cells (N2a) stably transfected with the “Swedish” mutant 
form of APP (SweAPP N2a Cells; APP695), a well-established model for 
mimicking Aβ overproduction characteristic of Alzhiemer’s disease were kind gifts 
from S. Gandy (Thomas Jefferson University, Philadelphia, PA, USA).  These 
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM), 10% 
fetal calf serum (FCS), and 200 µg/ml G418 (for selection).  Prior to treatment 
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N2a cells were differentiated in serum-free Neurobasal medium supplemented 
with 300 µM dibutyryl-cAMP for 4 hours. 
2.3 Sample Processing/ELISA 
2.3.1 Lysate preparation 
All cultured cells were lysed in ice-cold lysis buffer (20 mM Tris, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, 1 
mM PMSF) for 5 minutes followed by scraping.  Lysates were collected and 
centrifuged at 14,000 x g for 15 minutes at 4°C.  Protein levels in cell lysate 
supernatants were determined and normalized by bicinchoninic acid assay (BCA; 
Pierce Biotechnology, Rockford, IL, USA) in accordance with the manufacturer’s 
instruction. 
2.3.2 Aβ ELISA 
Conditioned media was collected and total Aβ1-40,42 species were quantified as 
previously described (Tan et al., 2002).  Briefly, 96-well immunoassay plates 
were coated with monoclonal anti-Aβ1-17 antibody (6E10; 2 µg/mL in PBS; 
Signet Laboratories, Dedham, MA, USA) overnight at 4 °C.  Plates were washed 
with 0.05% Tween 20 in PBS 5 times and incubated with blocking buffer (PBS 
with 1% bovine serum albumin (BSA), 5% horse serum) for 2 hours at room 
temperature.  Conditioned media and standards were added to the plates, 
following appropriate dilutions, and incubated overnight at 4 °C.  Following 3 
washes, biotinylated anti-Aβ17–26 monoclonal antibody (4G8; 0.5 µg/mL in PBS 
with 1% BSA; Signet Laboratories) was added to the plates and incubated for 2 
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hours at room temperature.  After 5 washes, streptavidin-horseradish peroxidase 
(HRP) (1:200 diluted in PBS with 1% BSA) was added to the 96-well plates for 30 
minutes at room temperature.  Tetramethylbenzidine (TMB) substrate was added 
to the plates and incubated for 15 minutes at room temperature. Stop solution 
(2N H2SO4) was added to stop the colorimetric reaction and optical density was 
determined immediately by a microplate reader at 450 nm.  ELISA values from 
were reported as % change from control or pg of Aβ/mg of total protein, as 
determined by BCA assay. 
2.3.3 sAPP-α ELISA 
Conditioned media was collected and sAPP-α levels were quantified using an 
sAPP-α sandwich ELISA protocol as previously described (Bailey, Giunta et al. 
2008).  High binding 96-well plates (Nunc, Denmark) were coated with 
monoclonal antibody 22C11 diluted in 100 µL (1 µg/mL) of carbonate buffer (pH 
9.6) and incubated overnight at 4°C.  The plate was washed five times with PBS-
Tween buffer (0.05% Tween 20) and blocked with 300 µL of blocking buffer (1% 
BSA, 5% Horse Serum in PBS) for 2 hrs at 37°C.  Synthetic sAPP-α protein 
(Abgent, San Diego, CA) was used as the positive control for this ELISA.  All 
samples were analyzed in duplicate.  100 µL samples of conditioned media were 
added to each well of the plate.  The plate was incubated for 2 hrs at 37°C. After 
washing 5 times, 100 µL of goat anti-human antibody 6E10 (Biosource; diluted 
1:3,000 in reagent diluent) was added to each well of the plate.  Following 2 
hour-incubation at 37°C and 5-time washing, 100 µL of anti-goat IgG conjugated 
with HRP (1:1500) was added to each well of the plate. The plate was incubated 
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for 1 hour at 37°C.  Following 5-time washing, 100 µL of substrate solution (TMB) 
was added to each well and plate was incubated at room temperature.  Twenty 
minutes later, 50 µL of stop solution (2 N H2SO4) was added to each well of the 
plate.  The optical density was determined using a microplate reader at 450 nm.  
Total intracellular protein was quantified using a BCA kit (Pierce Biotechnology, 
Rockford, IL) in accordance with the manufacturer's instructions.  Data was 
reported as ng of sAPP-α/mg of total intracellular protein produced per well. 
2.4 Syntheses 
2.4.1 NanoEGCg synthesis 
Nanolipidic particles (NanoEGCg) are prepared using a proprietary (US 
Provisional Patent Application #61/238,381) co-solubilization methodology 
involving use of monophasic liquid preparations developed by Nature’s Defense 
Systems, Tampa, Florida.  These particles have a defined size range from 30 to 
80nm. To form NanoEGCg co-solubilization methodology involving use of 
monophasic liquid preparations will be employed with proprietary starting 
materials. These materials are first solubilized into a water-in-ethanol solution 
(Step 1).  Anhydrous EGCg was added to the materials in Step 1 and co-
solubilized by mixing at room temperature (Step 2).  NanoEGCg particles were 
formed by the addition of distilled water while mixing materials (Step 3).  The final 
preparation of NanoEGCg particles was stirred for an additional 10 minutes prior 
to subjecting the preparation to sizing analysis with a Wyatt DynaPro Multiwell 
Reader (Wyatt Technology Corporation, Santa Barbara, California).  The stock 
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formulations were stored at 20˚C and protected from light until needed for no 
longer than 3 weeks to ensure integrity. 
2.4.2 Bulk cocrystal synthesis 
The cocrystals were made in bulk for dissolution study by slurry method.  For 
each cocrystal stoichiometric amounts of the starting materials in 5-6 mL of 
ethanol and stirred overnight with the help of a magnetic stir bar on a stir plate, 
which produces the cocrystals with 100% yield.  The purity of the bulk material is 
tested by powder X-ray diffraction (PXRD) and differential scanning calorimetry 
(DSC).  For PXRD pattern of the bulk material is compared to the PXRD obtained 
from the single crystal X-ray diffraction and presence of any additional peaks 
other than the peaks in the calculated pattern indicates starting materials or 
impurities.  Likewise, the DSC of the bulk cocrystal exhibits endotherm for the 
melting point of the cocrystals and the desolvation/dehydration. 
2.5 Cocrystal characterization 
2.5.1 Differential scanning calorimetry (DSC) 
Thermal analysis was performed on a TA Instruments DSC 2920 Differential 
Scanning Calorimeter.  Aluminum pans were used for all samples and the 
instrument was calibrated using an indium standard.  For reference, an empty 
pan sealed in the same way as the sample was used.  Using inert nitrogen 
conditions, the samples were heated in the DSC cell from 30 °C to the required 
temperature (melting point of the cocrystal) at a rate of 10 °C/min.  
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2.5.2 Powder x-ray diffraction (PXRD) 
A Bruker AXS D8 powder diffractometer was used for all PXRD measurements 
with experimental parameters as follows: Cu Kα radiation (λ = 1.54056 Ǻ); 40 kV 
and 30 mA. Scanning interval: 3–40° 2θ; time per step: 0.5 sec.  The 
experimental PXRD patterns and calculated PXRD patterns from single crystal 
structures were compared to confirm the composition of bulk materials. 
2.5.3 Single crystal x-ray data collection and structure determinations 
Crystals suitable for X-ray crystallography were selected using an optical 
microscope.  Single crystal X-ray diffraction data were collected and analyzed on 
a Bruker-AXS SMART-APEX CCD diffractometer with monochromatized Mo Kα 
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low temperature device. 
2.5.4 Cocrystal water solubility 
Each of the cocrystals was synthesized in bulk by taking stoichiometric ratios of 
the starting materials in methanol and slurrying them for 24 hours, which 
produced the cocrystals in 100% yield.  The slurries were dried at room 
temperature and were sieved to attain a particle size between 53 and75 µm.  The 
solubility study was done by taking approximately 4 grams of the cocrystal in 30 
mL of water and was stirred with magnetic stir bar at ca. 125 rmp for 24 hours.  
Aliquots were drawn from the slurry and filtered using a 0.45 µm nylon filters.  
The remaining solid was analyzed by PXRD and DSC and determined to be the 
cocrystal and not just a mixture of the starting materials.  For every cocrystal, 
1mL of the filtered solution from the slurry was transferred into a pre-weighed 
(w1) vial by using an analytical balance and was put on a hot plate (maintained at 
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50 oC) to evaporate the water.  The vial was weighed again (w2) and the 
difference in the weights (w2-w1) gave the weight of the cocrystal in 1ml of water 
from which the weight of the API was calculated. The solubility studies and the 
gravimetric methods were done in replicates of three.  Since the solubility of 
quercetin dihydrate is so low, it was impossible to obtain experimentally using our 
gravimetric method.  Therefore, we used the reported solubility from the literature 
for comparison (Srinivas, King et al. 2010).   
2.6 Intragastric gavage 
All animals were food (not water) deprived for 18 hours prior to the start of the 
experiment.  All formulations were delivered to the animals via oral gavage.  The 
dosage used for all APIs was 100 mg/kg.   
2.7 Chromatography 
2.7.1 EGCg liquid chromatography with tandem mass spectroscopy 
To accurately quantify the concentration of EGCg in the plasma, a previously 
described method was employed using liquid chromatography with tandem mass 
spectrometry (Wang, Hop et al. 2000; Sparidans, Lagas et al. 2007; Wang and 
Miksa 2007). 
Stock preparation 
A 2.00 mg/mL stock solution of EGCg in DMSO was prepared. The standard 
spiking solutions were prepared by diluting the stock solution to 1000 and 100 
µg/mL using acetonitrile:water (1:1, v:v). Both solutions were protected from light 
using amber vials and all solutions were stored at −20 ◦C. 
Standard curve preparation 
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For this analysis two standard curves were prepared one with a higher (10–0.100 
µg/ml) dynamic range the other a lower (1000–10ng/ml). Both standard curves 
were prepared using the appropriate blank plasma containing the preservative. 
The results indicated that the standard curve performance was within acceptable 
range for bioanalytical method acceptance (R2>0.99) (Sparidans et al., 2007; 
Wang and Miksa, 2007; Wang et al., 2000). 
2.7.2 Quercetin liquid chromatography with tandem mass spectroscopy 
The plasma samples were analyzed for QUE content by the Burnham Institute for 
Medical Research Pharmacology Core (Orlando, FL).  To accurately quantify the 
concentration of QUE in the plasma, a previously described method was 
employed using liquid chromatography with tandem mass spectrometry (Wang 
and Morris 2005).  The standards were prepared as follows.  A 2.00 mg/mL stock 
solution of QUE was accurately prepared in DMSO.  The stock solution was 
protected from light using amber vials and stored at -20°C.  Standards were 
prepared using the appropriate blank rat plasma with the ascorbic acid and 
EDTA preservative.  The samples were aliquotted into pre-labeled 1.7 mL 
microcentrifuge tubes.  100 µL was used as the aliquot volume for all samples.  
Except for the double blanks, 400 µL of the internal standard spiking solution 
(Naproxen, 2.00 µg/mL in ACN) was added to all samples.  Tubes were then 
capped, vortexed for 3 minutes and centrifuged for 10 minutes at 14,000 rpm.  
Approximately 300 µL was then transferred from each tube into a 96-well plate 
for analysis by LCMSMS.  The concentration range of the standard curve was 10 
µg/mL to 0.100 µg/mL of QUE.  The results indicated that the standard curve 
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performance was within acceptable range for bioanalytical method acceptance 
(R2> 0.99) (Wang, Hop et al. 2000; Sparidans, Lagas et al. 2007; Wang and 
Miksa 2007). 
2.8 Pharmacokinetic parameter calculations 
Mean plasma EGCg concentrations ± the standard error in the mean (SEM) was 
calculated using GraphPad PRISM software (GraphPad Software, Inc.).  
Pharmacokinetic graphs and parameters were determined using GraphPad 
PRISM.  Pharmacokinetic parameters included Cmax, Tmax, T1/2, area under curve 
(AUC), and relative bioavailiblity (Frel).  Relative bioavailibility was determined by 
dividing the AUC of each NanoEGCg formulation by the AUC of the control. 
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CHAPTER 3 
 
NANOLIPIDIC PARTICLES IMPROVE THE BIOAVAILABILITY AND ALPHA-
SECRETASE INDUCING ABILITY OF EPIGALLOCATECHIN-3-GALLATE 
(EGCg) FOR THE TREATMENT OF ALZHEIMER'S DISEASE 
 
3.1 Introduction 
The deterioration, malfunction, or death of neurons is a common 
etiological factor in several diseases including Alzheimer’s Disease (AD) and 
HIV-associated dementia (HAD) (Wojtera, Sikorska et al. 2005; Alisky 2007).  As 
the number of elderly individuals continues to rapidly increase, 
neurodegenerative disease, marked by progressive loss of mnemonic and higher 
cortical functions, has led to a massive socioeconomic burden which is projected 
to worsen (Tarkowski, Liljeroth et al. 2003).  Specifically, some 15% of the 
population greater than 65 years of age suffers from dementia (Meeuwsen, 
German et al. 2009).  Its presentation is heterogeneous as it is caused by 
multiple disorders.  Alzheimer’s disease (AD) and vascular dementia (VaD) are 
the two main causes of dementia affecting between 25–45% and 15–35%, 
respectively, of all patients suffering from dementia (Burns and Iliffe 2009).  
Among dementias where brain infectious viruses are etiologic, human 
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immunodeficiency virus type 1 (HIV-1) associated dementia (HAD) is the most 
common cause of dementia (Ghafouri, Amini et al. 2006).  Prevention of 
amyloidogenic processing of amyloid precursor protein with the use of natural 
phytochemicals capable of enhancing α-secretase activity may be a therapeutic 
approach for treatment of neurodegenerative diseases including Alzheimer’s 
disease (AD) and HIV-associated dementia (HAD).  We have previously shown 
that modulation of apoptosis cascades (Giunta, Obregon et al. 2006; Giunta, 
Zhou et al. 2008), and APP (amyloid precursor protein) processing (Rezai-
Zadeh, Shytle et al. 2005; Obregon, Rezai-Zadeh et al. 2006; Rezai-Zadeh, 
Shytle et al. 2008) with the green tea polyphenol, (-)-epigallocatechin-3-gallate 
(EGCg) is a plausible therapy in mouse models of AD and HAD.  In spite of these 
preclinical works, translating them to a human clinical trial has presented 
problems, primarily as a result of inefficient systemic delivery and bioavailability 
issues.  To achieve maximum response of a neuroprotective agent, novel 
strategies are required to enhance the oral bioavailability of potentially useful 
agents.  Self-assembled polymer micelles based on amphiphilic block 
copolymers have attracted substantial interest as delivery vehicles particularly for 
anti-cancer drugs (Yokoyama, Fukushima et al. 1998; Bontha, Kabanov et al. 
2006; Liu, Lee et al. 2006; Tian, Bromberg et al. 2007; Huynh, Passirani et al. 
2009; Kim, Kabanov et al. 2009; Siddiqui, Adhami et al. 2009).  Additionally, lipid 
carriers with incorporated drugs have been demonstrated to increase the 
absorption and circulation time in the body versus stand-alone compounds 
secondary to minimized renal clearance (Maeda 2001; Huynh, Passirani et al. 
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2009).  This study investigated the ability of nanolipidic particle complexes for 
increasing the oral bioavailability of EGCg.  These nanoparticles (NanoEGCg) 
differ from traditional liposomes because they do not require micelle formation.  
Rather, they are drug:lipid complexes.  This enables the formation of smaller 
diameter particles that we hypothesized would be useful for increasing the oral 
bioavailability of EGCg.   
3.2 Materials and Methods 
3.2.1 Reagents 
 Green tea-derived EGCg (>95% purity by HPLC) was purchased from 
www.herbs-tech.com. The BCA protein assay kit was purchased from Pierce 
Biotechnology (Rockford, IL, USA). Anti-human amyloid-β antibodies 4G8 and 
6E10 were obtained from Signet Laboratories (Dedham, MA, USA) and 
Biosource International (Camarillo, CA, USA), respectively. 
3.2.2 Preparation of Nanolipidic EGCg Particles (NanoEGCg) 
NanoEGCg was prepared as described in 2.4.1.  Six nanoparticle formulations 
were prepared for the study with various ratios of lipid carrier to EGCg.  
Formulations prepared for this study were 1:1, 1:2, 1:4, 1:8, 1:16, 1:32 
(Nanocarrier material to EGCg on a mg/mg basis).  Each formulation was 
subjected to sizing analysis using a Wyatt DynaPro Multiwell Reader (Wyatt 
Technology Corporation, Santa Barbara, California).  This data is presented in 
figure 3.1.  The particle size was found to range from 30 to 80 nm.   
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Figure 3.1 
Dynamic light scattering data.  A Wyatt DynaPro Multiwell Reader was used to 
characterize the diameter of the NanoEGCg particles.  The data indicates a 
narrow size distribution, with a cumulants mean of 49.5nm and polydispersity of 
0.052.   
 
3.2.3 Rats 
 Male Sprague Dawley rats weighing 200–250 g were purchased from 
Harlan Laboratories (Indianapolis, IN).  The rats were pre-cannulated by Harlan. 
The rounded tip catheters were surgically implanted into the jugular vein of the 
rats making multiple, precise blood draws painless to the animal.  The rats were 
food (not water) deprived for 18 h prior to the start of the experiment.  The EGCg 
formulations were delivered via oral gavage at a dosage of 100 mg EGCg/kg 
body weight (n=3 per group; 9 total).  Blood was collected at the following time 
points: 0, 5, 10, 30, 60, 120, 240, and 480 min.  Because heparin was kept in the 
catheter lines to prevent clotting, a small amount of blood was drawn and 
discarded before collecting each sample. Approximately 300ჼμL of blood was 
collected in EDTA tubes for each time point.  The samples were kept on ice to 
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preserve their integrity, then centrifuged at 4000 rpm for 10 min, after which the 
plasma was transferred to sterile centrifuge tubes.  A preservative solution was 
added to each plasma sample at 10% (v/v) concentration to ensure the integrity 
of the EGCg during storage (Lambert, Lee et al. 2006).  This preservative was 
comprised of 20% ascorbic acid (to prevent oxidation of EGCg) and 0.1% EDTA 
(to scavenge any metal contaminants).  The samples were stored at −80 ◦C until 
they were analyzed for EGCg content via LC-MSMS.  The LC-MSMS method is 
described in 2.7.1.   
3.2.4 Bioactivity assessment of NanoEGCg formulations 
Murine neuroblastoma cells that were stably transfected with the human APP 
gene (APP; SweAPP N2a cells) were cultured in 24-well tissue-culture plates at 1 
x 105 cells/well (n = 2 for each condition) with 0.5 mL of complete medium (MEM 
medium with 10% fetal calf serum).  Prior to treatment, the MEM was aspirated 
and replaced with 0.5 mL of neurobasal media and differentiated with cAMP for 4 
hours.  Following differentiation, the cells were treated with various nanoparticle 
formulations and controls (25µM - 3µM) for 18 hours.  Controls included two 
formulations of EGCg without a lipid carrier: one dissolved in water and another 
in ethanol and water at the same ratio that the nanoparticles were formed (2.4.1).  
The conditioned media was collected and sAPP-α levels were quantified using a 
sAPP-α sandwich ELISA protocol as described in 2.3.3.   
3.2.5 Pharmacokinetic screening of EGCg formulations in rats 
Male Sprague Dawley rats weighing 200-250 g were purchased from Harlan 
Laboratories (Indianapolis, IN).  The rats were pre-cannulated by Harlan.  The 
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rounded tip catheters were surgically implanted into the jugular vein of the rats 
making multiple, precise blood draws painless to the animal.  The rats were food 
(not water) deprived for 18 hours prior to the start of the experiment.  The EGCg 
formulations were delivered via oral gavage at a dosage of 100 mg EGCg/kg 
body weight.  Blood was collected at the following time points: 0, 5, 10, 30, 60, 
120, 240, and 480 minutes.  Because heparin was kept in the catheter lines to 
prevent clotting, a small amount of blood was drawn and discarded before 
collecting each sample.  Approximately 300 µL of blood was collected in EDTA 
tubes for each time point.  The samples were kept on ice to preserve their 
integrity, then centrifuged at 4000 rpm for 10 minutes, after which the plasma 
was transferred to sterile centrifuge tubes.  A preservative solution was added to 
each plasma sample at 10% (v/v) concentration to ensure the integrity of the 
EGCg during storage (Lambert, Lee et al. 2006).  This preservative was 
comprised of 20% ascorbic acid (to prevent oxidation of EGCg) and 0.1% EDTA 
(to scavenge any metal contaminants).  The samples were stored at -80°C until 
they were analyzed for EGCg content. 
3.2.6 Quantification of EGCg in Rat Plasma 
The plasma samples were blinded and sent to be analyzed for EGCg content by 
the Burnham Institute for Medical Research Pharmacology Core (Orlando, FL).  
The LC-MSMS method described in 2.7.1 was utilized.   
3.2.7 Pharmacokinetic Calculations 
Mean plasma EGCg concentrations ± the standard error in the mean (SEM) were 
calculated using GraphPad PRISM software (GraphPad Software, Inc.).  
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Pharmacokinetic graphs and parameters were determined using GraphPad 
PRISM.  Pharmacokinetic parameters included Cmax, Tmax, area under curve 
(AUC), and relative bioavailiblity.  Relative bioavailibility was determined by 
dividing the AUC of each NanoEGCg formulation by the AUC of the control. 
3.2.8 Statistical Analysis 
sAPP-α ELISA 
A Two-way ANOVA was performed using GraphPad PRISM software (GraphPad 
Software, Inc.).  This was followed by Bonferonni post-tests to assess the 
significance of each NanoEGCg formulation versus the EGCg/10%EtOH/H2O 
Control at each concentration.   
Pharmacokinetics 
A Two-way ANOVA was performed using GraphPad PRISM software (GraphPad 
Software, Inc.).  This was followed by Bonferonni post-tests to assess the 
significance of the 1:16 NanoEGCg formulation versus the EGCg/10%EtOH/H2O 
Control at each time point. 
3.3 Results 
3.3.1 Encapsulating EGCg increases sAPP-α generation in cultured 
SweAPP N2a cells  
We utilized an in vitro model for Alzheimer’s disease to test the hypothesis that 
formation of nanoparticle complexes would increase the bioactivity of EGCg by 
promoting α-secretase activity in cultured SweAPP N2a cells.  These cells 
overproduce human APP, making them ideal for screening compounds that 
modulate APP processing (Obregon, Rezai-Zadeh et al. 2006).  Additionally, we 
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used this assay as a criterion to select the most effective nanoparticle 
formulations to carry through to the pharmacokinetic pilot study.  Figure 3.2 
shows the mean ng of sAPP-α per mg of total protein produced ± standard 
deviation for all EGCg formulations.  Because ethanol was used to solubilize the 
lipid carrier and EGCg during the NanoEGCg productions process, it was 
appropriate to include a similarly formulated EGCg solution (10% EtOH solution 
v/v) to rule out any potential gains in α secretase activity being due to the alcohol 
content of the nanoparticle formulations.   
From figure 3.2, not all NanoEGCg formulations were effective.  In fact, the 1:1 
and 1:2 formulations were outperformed by the EGCg and 10%EtOH/H2O 
control at all concentrations tested.  The 1:8 and 1:16 NanoEGCg formulations 
were selected to be advanced to the pharmacokinetics phase of the study 
because they outperformed the control at all concentrations tested.  The 1:8 
formulation was statistically significant at all concentrations, whereas the 1:16 
was only statistically significant at the lower two concentrations.  Not only did 
these formulations show marked increases in sAPP-α generation but, perhaps 
more importantly, they continued to promote enhanced levels of α secretase 
activity even at the lowest EGCg concentration tested.   
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Figure 3.2 
Estimated sAPP-α generation for each treatment group.  The sAPP-α 
concentration (ng/ml) was normalized to the total protein content (mg/ml).  Data 
is presented as mean ng of sAPP-α per mg of total protein produced ± standard 
deviation.  The 1:8 and 1:16 formulations were superior to the other formulations, 
with the 1:8 showing 92% improvement in α secretase activity over the EtOH 
control at the 3µM concentration.  The 1:8 NanoEGCg formulation was 
statistically higher than the control at all concentrations tested.  The 1:16 
NanoEGCg formulation was statistically higher at the lower two concentrations 
(*** P<.001, **P<.01, *P<.05).   
 
3.3.2 Encapsulation improves the bioavailability of EGCg in rats  
There have been numerous groups to report the poor oral bioavailability of EGCg 
(Cai, Anavy et al. 2002; Lambert, Hong et al. 2004; Zhang, Zheng et al. 2004; 
Feng 2006; Lambert, Sang et al. 2006; Chan, Zhang et al. 2007; Lin, Wang et al. 
2007; Henning, Choo et al. 2008).  Recent reports suggest that this poor oral 
bioavailability is mostly due to factors such as poor absorption and intestinal 
metabolism, rather than elimination via first pass metabolism (Cai, Anavy et al. 
2002).  Larger lipid-based bilayer delivery systems have been shown to increase 
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the absorption of poorly permeable compounds (Allen 1998).  This preliminary 
study evaluated the ability of proprietary lipid nanoparticle complexes to increase 
the oral bioavailability of EGCg in rats.  Our results indicate that nanoparticles 
are highly effective at increasing the absorption of EGCg into systemic 
circulation.  Figure 3.3 shows a compilation of the mean pharmacokinetic curves 
for the nanoparticle formulation tested and the control.  Because EGCg is poorly 
water soluble, 10% EtOH was added to fully solubilize the EGCg at a 
concentration equivalent to the NanoEGCg stock (50mg/ml) and ensure accurate 
dosing in the control.  Our data suggests that the nanoparticle formulations result 
in substantial increases in the absorption of EGCg.  Although Figure 3.3 indicates 
only one NanoEGCg curve, both 1:8 and 1:16 formulations were tested.  
However, both nanoparticle formulations were similarly absorbed and not 
statistically different, so the 1:16 preperation was selected to represent the 
NanoEGCg pharmacokinetic curve.  The control was very poorly absorbed in 
comparison to the NanoEGCg.  Statistical significance (**P<.01) was observed at 
the 5 and 10-minute time points.  Table 3.1 shows some important 
pharmacokinetic parameters: Cmax, Tmax, AUC, and relative bioavailiblity.  The 
relative bioavailability (defined by the AUC) of the NanoEGCg was 2.31 and 2.50 
for the 1:16 and 1:8 formulations, respectively, in comparison to the free EGCg in 
10%EtOH solution (10%EtOH Control).   
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Figure 3.3 
EGCg pharmacokinetic curve (mean plasma concentration ± SEM vs. time) for 
the 1:16 NanoEGCg formulation (n=3) and free EGCg in 10%EtOH solution 
(n=3).  The nanoparticle formulation resulted in substantial increase in systemic 
EGCg absorption.  Statistical significance (**P<.01) was observed at the 5 and 
10-minute time points.  The 10% EtOH control had very poor absorption, with 
plasma concentration peaking at 116.57 ng/ml.  In comparison, the 1:16 
NanoEGCg reached a maximum plasma concentration of 599.33 ng/ml.   
 
Table 3.1 Pharmacokinetic Parameters 
Treatment Cmax Tmax 
AUC  
(0-240min) 
Relative 
Bioavailability 
EGCg+10% EtOH 
(Control) 116.57 5 14621 1 
NanoEGCg (1:16) 599.33 10 33722 2.31 
NanoEGCg (1:8) 704.67 5 36524 2.50 
 
3.4 Discussion and Conclusion 
Nanoparticles and larger liposomes have been investigated extensively for 
increasing the oral bioavailability of poorly absorbed compounds (Pandey, 
Ahmad et al. 2005; He, Horn et al. 2007; Kumar, Chandrasekar et al. 2007; 
Frezard, Martins et al. 2008; Rao, Yajurvedi et al. 2008).  It has been recently 
reported that encapsulating EGCg into liposomes can improve its anti-cancer 
efficacy (Siddiqui, Adhami et al. 2009) and antioxidant capacity (Italia, Datta et al. 
2008), probably by increasing its bioavailability.  However, these studies utilized 
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larger diameter particles (>100nm) and focused primarily on improved efficacy of 
EGCg for specific disease modifying parameters.  Here, we have tested the 
ability of small diameter nanolipidic particle formation as a method for increasing 
not only the α-secretase inducing ability of EGCg, but also its oral bioavailability. 
 It has been shown that an oral dose of 800mg/70kg/day provides 
approximately 400ng/ml EGCg in human plasma (Chow, Cai et al. 2001).  Given 
that we have recently shown that 1000 - 2000ng/mL of free EGCg is necessary 
for promoting APP α-secretase cleavage in SweAPP N2a cells (Rezai-Zadeh, 
Shytle et al. 2005), using linear approximation, an oral dose of EGCg of 
1800mg/70kg/day would be required to reach therapeutically effective plasma 
concentrations of EGCg.  From a safety and practicality point of view, this dose 
might be unacceptable for clinical trials (Ullmann, Haller et al. 2003; Ullmann, 
Haller et al. 2004).  Since the oral EGCg dosage in most clinical trials for cancer 
therapy is typically not more than 800 mg/day (Chow, Cai et al. 2001) regimens 
which enhance EGCg bioavailability, effecting reductions in neuropathology and 
cognitive decline at minimum doses, are very desirable.  Thus, the bioavailability 
of EGCg is an important issue for oral administration of EGCg to clinical trials. 
It has been previously reported that decreased bioavailability of EGCg is 
greatly associated with the glucuronidated form, which is largely present in the 
plasma of treated mice (Lambert, Lee et al. 2003).  Additionally, it has been 
shown that piperine, an alkaloid derived from black pepper, enhances the 
bioavailability of EGCg by inhibiting glucuronidation (Lambert, Hong et al. 2004).  
Unfortunately the consumption of piperine also influences the metabolism of all 
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other ingested food and drugs (Khajuria, Thusu et al. 2002).  For example it 
increases the plasma concentration of phenytoin (Pattanaik, Hota et al. 2006), 
propanalol, and theophylline in healthy volunteers (Bano, Raina et al. 1991) and 
plasma concentrations of rifamipicin (rifampin™) in patients with pulmonary 
tuberculosis (Zutshi, Singh et al. 1985).  By forming EGCg nanolipidic complexes 
as we have, it is possible to increase the oral bioavailability of EGCg as well as 
its AD and HAD preventative and therapeutic actions, without affecting the 
absorption of other ingested compounds.  This may be an important factor to 
consider when bringing an EGCg therapeutic into the clinical setting.   
 In this study, we have modified EGCg such that it requires no co-
administration of other drugs.  Rather, it is co-solubilized with a lipid carrier using 
proprietary methodology to form 30-80nm diameter nanoparticle complexes.  The 
importance of particle diameter for drug delivery is particularly important for 
delivery of drugs to the brain (Wissing, Kayser et al. 2004).  Previously, even 
smaller diameter liposomes (100nm) have had trouble penetrating the tight 
junctions between the endothelial cells of the blood brain barrier without osmotic 
disruption (Sakamoto and Ido 1993).  This highlights an important distinction 
between this nanoparticle technology and previous liposomal technologies, which 
require micelle formation.  NanoEGCg does not involve encapsulating the EGCg 
into a micelle.  Instead, lipid:EGCg complexes are formed.  Because the EGCg is 
not fully encased in a micelle structure, it is possible to achieve smaller diameter 
particles without compromising the stability of the carrier.  Although this 
preliminary study has demonstrated the ability of nanoparticles to increase the 
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systemic absorption of EGCg taken orally, it is likely that the small diameter of 
these particles will also lead to improved blood brain barrier penetration.  Further 
studies will be performed to investigate the possibility that nanolipidic particles 
can be used to enhance the delivery of poorly absorbed drugs to the brain.   
This study provides important preliminary evidence that nanolipidic 
particles might be useful for safely translating EGCg into human clinical trials.  
Not only did NanoEGCg more than double the oral bioavailability of EGCg in rats 
(Figure 3.3) but also was more effective at promoting α-secretase activity in vitro, 
even at reduced concentrations (Figure 3.2).  Taken together, it is possible that 
NanoEGCg will be therapeutically effective at doses that would be considered 
acceptable in the clinical setting.   
  
	   	  32	  
 
 
 
 
 
CHAPTER 4 
 
COCRYSTALS OF QUERCETIN WITH IMPROVED SOLUBILITY AND ORAL 
BIOAVAILABILITY 
 
 
4.1 Introduction 
Flavonoids in general are widely studied and have been found to promote 
healthy living in epidemiologic studies (Hertog 1996; Arts 2008).  Quercetin, 
3,3',4',5,7-Pentahydroxyflavone, (QUE) is one of the most common dietary 
flavonoids and is found throughout the plant kingdom (Figure 1).  A typical 
Western diet was estimated to provide between 0 and 30 mg of QUE per day, 
most of which is consumed as tea, red wine, fruits and vegetables (Egert, 
Wolffram et al. 2008).  This not only supports its safety for consumption by 
humans (albeit at a low dose), but also provides epidemiological evidence for its 
beneficial effects.  QUE is perhaps best known for its antioxidant activity but has 
numerous other biological and pharmacological effects including metal chelation, 
anti-carcinogenic, cardioprotective, bacteriostatic, and antiviral activity (Vargas 
and Burd ; Bakay, Mucsi et al. 1968; Formica and Regelson 1995; Spencer, 
Kuhnle et al. 2003; Leopoldini, Russo et al. 2006; Murakami, Ashida et al. 2008).   
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 Even though QUE has been found to have many potential beneficial 
effects, its usefulness in vivo is questionable due to unfavorable 
pharmacokinetics in its pure form.  The bioavailability of QUE has been studied 
extensively (Hollman, van Trijp et al. 1997; Manach, Morand et al. 1997; Graefe, 
Derendorf et al. 1999; Manach, Texier et al. 1999; Ader, Wessmann et al. 2000; 
Graefe, Wittig et al. 2001; Cermak, Landgraf et al. 2003; Lesser, Cermak et al. 
2004; Erlund, Freese et al. 2006).  Unfortunately, it appears that QUE is 
absorbed poorly, is highly susceptible to metabolic conjugation, and exists mostly 
as a conjugated form in systemic circulation, resulting in low bioavailability 
(Manach, Texier et al. 1999; Ader, Wessmann et al. 2000).  Furthermore, QUE 
bioavailability has been evaluated in humans following a single 4 g oral dose.  
The investigators reported that following oral administration, no measurable 
plasma or urine QUE concentrations could be detected (Gugler, Leschik et al. 
1975).  They concluded that less than 1% of the QUE was absorbed unchanged 
in the gastrointestinal tract (Gugler, Leschik et al. 1975).  This is not surprising 
given that QUE has extremely low water solubility, a major factor in drug 
absorption.  Not only is QUE absorbed poorly, but also it is conjugated 
extensively in the liver following oral administration (Reinboth, Wolffram et al. ; 
Manach, Morand et al. 1997; Ader, Wessmann et al. 2000).  In dogs, more than 
80% of the circulating flavonols existed as conjugated metabolites (Reinboth, 
Wolffram et al.).  Since many of the proposed health effects of QUE were 
observed in vitro with the unconjugated aglycone, it is questionable whether the 
QUE metabolites will remain bioactive.  Few investigators have studied the 
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bioactivity of QUE metabolites and those that do typically only look at one 
potential clinical indication for QUE.  Spencer et al studied the bioactivity of in 
vivo QUE metabolites.  They found that 3′-O-methyl quercetin and 4′-O-methyl 
quercetin had a reduced capacity to protect fibroblasts from peroxide-induced 
cell damage, whereas quercetin 7-O-β-D-glucuronide was completely inactive 
(Spencer, Kuhnle et al. 2003).  Even though this study only investigated one 
activity of QUE, it is probable that the in vivo effectiveness of QUE will be limited 
by its absorption and metabolism.   
 Thus, novel strategies that can increase the absorption of QUE or affect 
its metabolism are desirable.  The pharmaceutical industry typically employs 
several methods for correcting compounds that exhibit undesirable 
physicochemical characteristics including screening for salts, polymorphs, and 
hydrates/solvates of the active pharmaceutical ingredient (API) (Shan and 
Zaworotko 2008).  However, one long known methodology has remained 
relatively unexplored by many.  Cocrystallization is beginning to attract the 
attention of the pharmaceutical industry because it can be used to both modify 
the physicochemical properties of a compound without affecting the intrinsic 
bioactivity and extend the product life of the API (Sarma, Chen et al. 2011).  
Cocrystals have been defined as “a multiple component crystal in which all 
components are solid under ambient conditions when in their pure form” (Shan 
and Zaworotko 2008).  The API and cocrystal former(s) exist at a stoichiometric 
ratio and form complexes that are generally stabilized by hydrogen bonds.  This 
technique has been used to improve the physicochemical properties of numerous 
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different APIs (Cheney, Weyna et al. ; Yadav, Dabke et al. ; Brader, Sukumar et 
al. 2002; Remenar, Morissette et al. 2003; Childs, Chyall et al. 2004; McNamara, 
Childs et al. 2006; Hickey, Peterson et al. 2007; Bak, Gore et al. 2008; Basavoju, 
Bostrom et al. 2008).  Most notably, cocrystallization is often used to modulate 
the solubility of an API.  Whenever solubility is a limiting factor in the 
bioavailability of a compound (like with QUE), modulation of solubility can 
produce drastic effects.  Thus, we determined that QUE would be a good 
candidate for cocrystallization.   
 In this report, we evaluate the solubility and pharmacokinetic profile of four 
novel QUE cocrystals.  Each of the cocrystals described were selected due to 
improved physicochemical properties that we hypothesized would lead to 
improved bioavailability.   
4.2 Materials and Methods 
4.2.1 Reagents 
Quercetin dihydrate (98% purity), Isonicotinamide (INM) (99% purity), Caffeine 
(CAF), and Theobromine (TBR) (98% purity) were purchased from Sigma-Aldrich 
Corporation (St. Louis, MO, USA).   
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4.2.2 Synthesis of the cocrystals 
 
Figure 4.1 
QUE cocrystal reaction sheme. 
 
QUECAF•MeOH: QUE dihydrate (34.0 mg, 0.101 mmol) and CAF (19.0 mg, 
0.100 mmol) were dissolved in 6 mL of methanol by heating.  The resulting 
solution was placed in a refrigerator overnight.  Golden yellow crystals of the 
cocrystal were harvested (melting point = 246oC).  
QUECAF: The cocrystal was prepared by desolvating QUECAF•·MeOH.  It was 
prepared by overnight slurrying of QUE dihydrate (101.46 mg, 0.300 mmol) and 
caffeine (58.23 mg, 0.300 mmol) in 2 mL of methanol.  The solid was filtered and 
dried in the vacuum oven for 3 hours at 150 oC, thereby affording QUECAF. 
(melting point of dried solid = 245.95oC). 
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QUEINM: QUE dihydrate (34.0 mg, 0.101 mmol) and INM (12.3 mg, 0.100 mmol) 
were dissolved in 6 mL of methanol by heating on a hotplate.  The resulting 
solution was placed in a refrigerator.  After 2 days, yellow plate crystals of 
QUEINM were obtained (melting point = 262oC). 
QUETBR•2H2O: QUE dihydrate (33.8 mg, 0.099 mmol) and TBR (18.0 mg, 0. 
099mmol) were dissolved in 5 mL of ethanol and 10 mL of 1:1 mixture of water 
and ethanol respectively by heating.  Resulting solutions were filtered together 
and placed in the refrigerator for slow evaporation. The crystals were harvested 
after 4 days (melting point = 293.8oC).  
Synthesis of cocrystals in bulk for dissolution: 
The cocrystals were made in bulk for dissolution study by slurry method.  For 
each cocrystal stoichiometric amounts of the starting materials in 5-6 mL of 
methanol and stirred overnight with the help of a magnetic stir bar on a stir plate, 
which produces the cocrystals with 100% yield.  The purity of the bulk material is 
tested by powder X-ray diffraction (PXRD) and differential scanning calorimetry 
(DSC).  For PXRD pattern of the bulk material is compared to the PXRD obtained 
from the single crystal X-ray diffraction and presence of any additional peaks 
other than the peaks in the calculated pattern indicates starting materials or 
impurities.  Likewise, the DSC of the bulk cocrystal exhibit endotherm for the 
melting point of the cocrystals and the desolvation/dehydration.  
4.2.3 Characeterization of Cocrystals 
Differential scanning calorimetry (DSC): Thermal analysis was performed on a 
TA Instruments DSC 2920 Differential Scanning Calorimeter.  Aluminum pans 
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were used for all samples and the instrument was calibrated using an indium 
standard.  For reference, an empty pan sealed in the same way as the sample 
was used.  Using inert nitrogen conditions, the samples were heated in the DSC 
cell from 30 °C to the required temperature (melting point of the cocrystal) at a 
rate of 10°C/min.  
Infrared spectroscopy (FT-IR): To characterize the cocrystals by infrared 
spectroscopy a Nicolet Avatar 320 FT-IR instrument was used.  Sample amounts 
of 1-2 mg were used and spectra were measured over the range of 4000–400cm-
1 and analyzed using EZ Omnic software. 
Ultraviolet/Visible Spectroscopy (UV/vis): UV/vis analysis was performed on a 
Perkin-Elmer Lambda 900 UV/VIS/NIR spectrometer. 
Powder X-ray diffraction (PXRD): A Bruker AXS D8 powder diffractometer was 
used for all PXRD measurements with experimental parameters as follows: Cu 
Kα radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA. Scanning interval: 3–40° 2θ; time 
per step: 0.5 sec.  The experimental PXRD patterns and calculated PXRD 
patterns from single crystal structures were compared to confirm the composition 
of bulk materials. 
Single-Crystal X-ray Data Collection and Structure Determinations: Suitable 
crystals for X-ray crystallography were selected using an optical microscope.  
The X-ray diffraction data were collected on Bruker-AXS SMART-APEXII CCD 
diffractometer using Cu Kα (λ = 1.54178 Å) for QUECAF•MeOH and Mo Kα 
radiation (λ = 0.71073 Å) for QUEINM. Indexing was performed using APEX2 
(2010) (Difference Vectors method). Data integration and reduction were 
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performed using SaintPlus 6.01 (2009).  Absorption correction was performed by 
multi-scan method implemented in SADABS (Sheldrick 2008).  Space groups 
were determined using XPREP implemented in APEX2 (2010).  The structure 
was solved using SHELXS-97 (direct methods) and refined using SHELXL-97 
(full-matrix least-squares on F2) contained in APEX2 (2010) and WinGX v1.70.01 
(Sheldrick 1990; Sheldrick 1997; Farrugia 1999) program packages. All non-
hydrogen atoms were refined anisotropically.  Hydrogen atoms were placed in 
geometrically calculated positions and included in the refinement process using 
riding model with isotropic thermal parameters: Uiso(H) = 1.5Ueq(-CH3,-OH), 
Uiso(H) = 1.2Ueq(-CH).  Hydrogen atoms of the NH2 group were found on a 
difference Fourier map and were freely refined.  
4.2.4 Solubility evaluation  
Solubility studies were performed on QUECAF•MeOH, QUECAF, QUEINM, and 
QUETBR•2H2O using 1:1 mixture of water and ethanol as QUE could not be 
quantified by using UV/VIS/NIR spectrophotometry in water alone. However the 
solubility of QUE and its dihydrate in water has been reported by Srinivas et al as 
0.00215 mg/mL and 0.00263 mg/mL respectively (Srinivas, King et al. 2010).  
Each of the cocrystal was synthesized in bulk by taking stoichiometric ratios of 
the starting materials in methanol and slurrying them for 24 hours, which 
produced the cocrystals in 100% yield.  The slurries were dried at room 
temperature and were sieved to attain a particle size between 53 and 75 µm.  
The solubility study was done by taking approximately 4 grams of the cocrystal in 
30 mL of water and was stirred with magnetic stir bar at ca. 125 rmp for 24 hours.  
	   	  40	  
The solubility studies were conducted by taking approximately 4 grams of the 
cocrystal in 70 mL of 50% ethanol and were stirred with magnetic stir bar at ca. 
125 rmp for 24 hours at room temperature. Aliquots were drawn from the slurry at 
regular time intervals (5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 105, 
120, 150, 180, 240 and 1440 minutes) and filtered using a 0.45 µm nylon filters. 
The filtrates were immediately diluted appropriately and were analyzed to 
measure the concentration of QUE by using UV/VIS/NIR spectrometer at 360 nm 
where the interference of the cocrystals formers was not observed.  The 
remaining solids were analyzed by PXRD and DSC. The solubility measurements 
were done in replicates of three. 
4.2.5 Pharmacokinetic screening of quercetin formulations in rats 
Male Sprague Dawley rats (n=3 per group) weighing 200-250 g were purchased 
from Harlan Laboratories (Indianapolis, IN).  The rats were purchased pre-
cannulated by Harlan.  The rounded tip catheters were surgically implanted into 
the jugular vein of the rats making multiple, precise blood draws painless to the 
animal.  The rats were food (not water) deprived for 18 hours prior to the start of 
the experiment. Vegetable oil was selected as the gavage vehicle because all 
crystal forms were observed to be insoluble in it.  The QUE formulations were 
delivered via oral gavage at a dosage of 100 mg quercetin/kg body weight.  
Blood was collected at the following time points: 0, 5, 10, 30, 60, 120, 240, and 
480 minutes.  Because heparin was kept in the catheter lines to prevent clotting, 
a small amount of blood was drawn and discarded before collecting each 
sample.  Approximately 300 µL of blood was collected in EDTA tubes for each 
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time point.  The samples were kept on ice to preserve their integrity, then 
centrifuged at 4000 rpm for 10 minutes, after which the plasma was transferred 
to sterile centrifuge tubes.  A preservative solution was added to each plasma 
sample at 10% (v/v) concentration to ensure the integrity of the QUE during 
storage (Lambert, Lee et al. 2006).  This preservative was comprised of 20% 
ascorbic acid (to prevent oxidation) and 0.1% EDTA (to scavenge any metal 
contaminants).  The samples were stored at -80°C until they were analyzed for 
QUE content. 
4.2.6 Quantification of QUE in Rat Plasma 
The plasma samples were analyzed for QUE content by the Burnham Institute for 
Medical Research Pharmacology Core (Orlando, FL).  To accurately quantify the 
concentration of QUE in the plasma, a previously described method was 
employed using liquid chromatography with tandem mass spectrometry (Wang 
and Morris 2005).  The standards were prepared as follows.  A 2.00 mg/mL stock 
solution of QUE was accurately prepared in DMSO.  The stock solution was 
protected from light using amber vials and stored at -20°C.  Standards were 
prepared using the appropriate blank rat plasma with the ascorbic acid and 
EDTA preservative.  The samples were aliquotted into pre-labeled 1.7 mL 
microcentrifuge tubes.  100 µL was used as the aliquot volume for all samples.  
Except for the double blanks, 400 µL of the internal standard spiking solution 
(Naproxen, 2.00 µg/mL in ACN) was added to all samples.  Tubes were then 
capped, vortexed for 3 minutes and centrifuged for 10 minutes at 14,000 rpm.  
Approximately 300 µL was then transferred from each tube into a 96-well plate 
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for analysis by LCMSMS.  The concentration range of the standard curve was 10 
µg/mL to 0.100 µg/mL of QUE.  The results indicated that the standard curve 
performance was within acceptable range for bioanalytical method acceptance 
(R2> 0.99) (Wang, Hop et al. 2000; Sparidans, Lagas et al. 2007; Wang and 
Miksa 2007). 
4.2.7 Pharmacokinetic Calculations 
Mean plasma QUE concentrations and the standard error in the mean (SEM) 
were graphed using GraphPad PRISM software (GraphPad Software, Inc.).  
Pharmacokinetic parameters were determined using a commercially available 
computer modeling program, PK Solutions v2.0.7 (Summit Research Services, 
Ashland, OH).  The reported pharmacokinetic parameters included CMAX, TMAX, 
area under curve (AUC), relative bioavailability (FREL), absorption half life (A T1/2), 
distribution half life (D T1/2), and elimination half life (E T1/2).  Relative 
bioavailability was determined by dividing the AUC of each QUE formulation by 
the control.   
Statistical Analysis 
A post hoc t-test with Bonferroni correction was used to assess the statistical 
significance at each time point for the pharmacokinetic study.  Each QUE 
cocrystal was compared to the QUE dihydrate control.  The criterion for rejection 
of the null hypothesis was P<0.05. 
4.3 Results 
4.3.1 Dissolution study of the QUE cocrystals 
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QUE has very poor water solubility.  In fact, when we tried to determine the water 
solubility of QUE dihydrate it was below our lower limit of detection.  Therefore, 
1:1 ethanol/water solvent mixture was used for the dissolution studies. The 
solubility of QUE dihydrate in 1:1 ethanol/water solvent mixture is found to be 
0.267 mg/mL.  We found that the QUECAF and QUECAF•MeOH cocrystals 
exhibit the highest solubilities.  The maximum solubilities exhibited by QUECAF, 
QUECAF•MeOH, QUEINM, QUETBR•2H2O cocrystals were 3.627, 2.018, 1.22 
and 0.326 mg/mL respectively. From the dissolution profiles it is evident that 
QUECAF (desolvated form of QUECAF•MeOH) displayed the highest 
concentration of QUE.  This cocrystal increased the solubility of QUE by 14 fold, 
and the lowest was by QUETBR•2H2O, which was only slightly improved over 
QUE alone. Figure 4.2 represents the dissolution profiles of QUE dihydrate and 
its cocrystals in the first 4 hours and Figure 4.3 in 24 hours. From the DSC and 
PXRD obtained from the leftover powders after 24-hour dissolution reveal that 
QUECAF, QUECAF•MeOH, QUETBR•2H2O and QUEINM convert back to QUE 
dihydrate.   
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Figure 4.2 
Dissolution profiles of QUE dihydrate and its cocrystals in 1:1 ethanol/water mixture (a) 
first 4 hours. 
 
 
Figure 4.3 
Dissolution profiles of QUE dihydrate and its cocrystals in 1:1 ethanol/water mixture (a) 
first 4 hours. 
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4.3.2 Pharmacokinetics of the QUE cocrystals 
We hypothesized that the improvements in solubility would lead to improved 
bioavailability for the QUE cocrystals.  This hypothesis was supported in our 
preliminary pharmacokinetic evaluation.  The pharmacokinetic curves are shown 
in Figure 4.4.   
Figure 4.4 
Pharmacokinetic profiles (mean plasma concentration + SEM versus time).  
There were n=3 rats per group.  Statistical significance was achieved for 
QUEINM at t=10 (p<0.01) and for QUECAF•MeOH at t=5 (p<0.001). 
 
As expected, the QUE dihydrate was absorbed very poorly.  In fact, only one of 
the three rats exhibited levels of QUE that were above our lower limit of 
quantification (0.100 µg/mL) and only at one time point, the TMAX, t=30 minutes.  
This is easily explained by the extremely poor solubility of QUE dihydrate.  
	   	  46	  
Because the QUE dihydrate was so poorly absorbed, we were unable to 
calculate half-life values for the three pharmacokinetic phases (absorption, 
distribution, and elimination).  All four of the cocrystals exhibited favorable 
solubility and improved pharmacokinetic parameters.  These pharmacokinetic 
parameters including the TMAX, CMAX, AUC, FREL, A T1/2, D T1/2, and E T1/2 can be 
found in Table 4.1.  Interestingly, the QUETBR•2H2O cocrystal was only slightly 
more soluble than QUE dihydrate but exhibited vastly superior pharmacokinetic 
properties.  The QUETBR•2H2O cocrystal had the highest FREL at 9.93.  This 
means that the AUC was nearly 10-fold higher than with QUE dihydrate.  
Additionally, the elimination of QUETBR•2H2O appears to be slowed.  The E T1/2 
was the highest for this cocrystal at 145 minutes (Table 4.1).  All of the cocrystals 
reached systemic circulation more quickly than the QUE control, which is 
consistent with the improved solubility.  Perhaps most importantly, the relative 
bioavailability (FREL) was much higher with the cocrystals. QUEINM had the 
second greatest FREL at 5.46, followed by the QUECAF•MeOH and QUECAF at 
4.01 and 2.57, respectively.  The E T1/2 followed the same trend as the FREL.  The 
QUEINM exhibited an E T1/2 of 77 minutes and the QUECAF•MeOH and 
QUECAF cocrystals were 52 and 26 minutes, respectively.   
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Table 4.1. Pharmacokinetic Parameters 
 QUE QUEINM QUECAF•MeOH QUECAF QUETBR•2H2O 
TMAX(min) 30 10 5 10 5 
CMAX(ng/mL) 285 1401 2612 656 840 
AUC (ng•min/mL) 7493 40921 30084 19232 74430 
FREL 1 5.46 4.01 2.57 9.93 
A T1/2 (min) N/A 3.260 2.378 2.682 1.656 
D T1/2 (min) N/A 5.291 5.091 3.568 8.610 
E T1/2 (min) N/A 76.934 52.447 26.381 145.309 
 
4.3.3 Crystal structures of the QUE cocrystals 
Table 4.2. Crystallographic data and structure refinement parameters for the 
cocrystals reported herein. 
 
 QUEINM QUECAF•MeOH 
Formula C21H16N2O8 C24H24N4O10 
MW 424.36 528.47 
Crystal system Triclinic Monoclinic 
Space group P-1 P2(1)/c 
a (Å) 4.978 (1) 10.309 (3) 
b (Å) 12.636 (3) 14.853(4) 
c (Å) 15.571 (3) 15.199 (5) 
α  (deg) 110.53 (3) 90 
β  (deg) 97.63 (3) 100.612 (2) 
γ  (deg) 99.39 (3) 90 
V /Å3  885.7 (3) 2287.51 (12) 
Dc/mg m-3 1.5913 1.535 
Z 2 4 
2θ  range 2.66 to 24.93  4.20 to 67.88 
Nref./Npara.  2999/292  4031/353 
T /K 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0592  0.0434 
wR2 0.1267  0.1090 
GOF 1.091  1.035 
Abs coef. 0.124  0.1033 
 
QUEINM:  The 1:1 cocrystal of QUEINM contains two molecules of QUE and 
INM in the unit cell and crystallizes in P-1 space group.  The catechol moiety of 
QUE molecules form the O···O-H supramolecular homosynthon with hydrogen 
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bond distance of 2.765 (3) Å.  The carbonyl and the syn-hydrogens of the amide 
functionality of INM molecules hydrogen bond to the catechol dimer on either 
side and results in the formation of a ring described by 𝐑𝟐𝟐   (8) graph set(Etter, 
MacDonald et al. 1990) (N-H···O:  2.610 (3) Å and O···O-H: 3.028 (4) Å).  Thus, a 
four-component assembly is generated by two molecules of INM and QUE 
molecules which can be described by 𝐑𝟒𝟒  (18) graph set.  The Narom and the anti-
hydrogen of the amide moiety of INM molecules interacts with one of the O-H 
moieties (O-H···Narom: 2.688 (3) Å· and the carbonyl moieties (O···N-H: 3.019 (3) 
Å of QUE molecule respectively.  The supramolecular interactions between QUE 
and INM molecules in QUEINM cocrystal overall lead to the generation of a 2-D 
sheet as shown in Figure 4.5.  
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Figure 4.5 
Representation of supramolecular sheet in QUEINM. In the the cocrystal the 
QUE and INM molecules interact via O-H···Narom supramolecular H-bonds. Two 
QUE molecules form the catechol dimer through O-H···O H-bonds and the amide 
functionalities of the INM molecules H-bond on either side of the catechol dimer. 
Overall H-bonding results in the generation of supramolecular sheet. 
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Table 4.2. Crystallographic data and structure refinement parameters for the cocrystals 
reported herein. 
 
 QUEINM QUECAF•MeOH 
Formula C21H16N2O8 C24H24N4O10 
MW 424.36 528.47 
Crystal system Triclinic Monoclinic 
Space group P-1 P2(1)/c 
a (Å) 4.978 (1) 10.309 (3) 
b (Å) 12.636 (3) 14.853(4) 
c (Å) 15.571 (3) 15.199 (5) 
α  (deg) 110.53 (3) 90 
β  (deg) 97.63 (3) 100.612 (2) 
γ  (deg) 99.39 (3) 90 
V /Å3  885.7 (3) 2287.51 (12) 
Dc/mg m-3 1.5913 1.535 
Z 2 4 
2θ  range 2.66 to 24.93  4.20 to 67.88 
Nref./Npara.  2999/292  4031/353 
T /K 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0592  0.0434 
wR2 0.1267  0.1090 
GOF 1.091  1.035 
Abs coef. 0.124  0.1033 
 
QUECAF•MeOH: This cocrystal crystallizes in a P21/c space group. The Narom of 
the imidazole ring and the CO of the imide ring of CAF interacts with O-H 
moieties of QUE through O-H···Narom (2.821 (3) Å) and CO···O-H (2.716 (3) Å) 
hydrogen bonds.  Both the O-H in the catechol moiety of QUE molecule 
hydrogen bond to the O-H of neighboring QUE molecule through O-H···O and 
O···O-H ((2.774 (3) Å and 2.847 (3) Å respectively).  Supramolecular 
heterosynthons: One of the O-H adjacent to the CO functionality engages in a 
strong intramolecular H-bonding (2.602 (3) Å).  The methanol molecule interacts 
with the remaining CO group on the imide ring of CAF molecule with a hydrogen 
bond distance of 2.712 (3) Å.  The overall interaction between QUE, CAF and 
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MeOH results in the formation of a supramolecular sheet as shown in Figure 4.6.   
 
 
 
 
 
 
 
 
Figure 4.6 
Intermolecular hydrogen bonding in QUECAF•MeOH. QUE molecules interact 
with CAF molecules through O-H···Narom and O-H···C=O supramolecular H-bonds 
and the MeOH molecules just interact with the CAF molecules. A supramolecular 
sheet is produced by hydrogen bonding between QUE, CAF and MeOH 
molecules. 
 
The MeOH molecules in one layer interact with one of the O-H of the catechol 
moieties of QUE in another supramolecular sheet through O···O-H hydrogen 
bonds.  This results in the formation of bilayers as shown in Figure 4.7.  
Figure 4.7 
Illustration of bilayers in QUECAF•MeOH. Each supramolecular sheet in 
QUECAF•MeOH interats with the other other sheets through MeOH molecules 
and results in the formation of bilayers which can be described as ABAB and so 
on. 
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The crystal structure of QUETBR•2H2O has been published elsewhere (Clarke, 
Arora et al. 2010).  The crystal structure of QUECAF has not been determined 
yet but the chemical identity of the cocrystal is confirmed from the PXRD, IR, 
DSC and TGA.  The PXRD reveals that QUECAF is isostructural to 
QUECAF•MeOH (Figure 4.8a) and the DSC confirms that after the loss of MeOH 
molecule from QUECAF•MeOH the cocrystal is still stable and has the same 
melting point as that of the solvated one (Figure 4.8b).   
	  
Figure 4.8a 
Comparison PXRDs of QUECAF•MeOH and QUECAF; (b) Comparison of DSCs 
of QUECAF•MeOH and QUECAF. The PXRD patterns of QUECAF•MeOH 
calculated and experimental (bulk powder) matches exactly indicating the total 
conversion of the starting materials into cocrystal and no presence of starting 
materials. The similarity in the PXRD patterns of QUECAF•MeOH and QUECAF 
indicates isostructural nature of both cocrystals. 
	   	  53	  
	  
Figure 4.8b 
Comparison of DSCs of QUECAF•MeOH and QUECAF. The DSC of QUECAF 
reveals that the crystal packing is intact even after the removal of MeOH 
molecule as its melting point matches with that of QUECAF•MeOH. 
 
4.4 Discussion and Conclusion 
Given that QUE exhibits numerous useful bioactivities it is not surprising 
that it remains to be studied even after the discovery of its poor bioavailability in 
1975 (Gugler, Leschik et al. 1975).  Since then, there have been several follow-
up reports of QUE deposition and bioavailability in various animal models 
(Manach, Morand et al. 1997; Manach, Texier et al. 1999; Ader, Wessmann et al. 
2000; Morand, Manach et al. 2000; Cermak, Landgraf et al. 2003; Khaled, El-
Sayed et al. 2003; Lesser, Cermak et al. 2004; Mullen, Rouanet et al. 2008).  
The reoccurring theme in the existing literature is that QUE is present in systemic 
circulation mainly as conjugated metabolites.  Piskula et al (1998) studied the 
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bioavailability of QUE in various vehicles in a rat model and reported circulating 
levels of QUE and its metabolites (Piskula and Terao 1998).  Not surprisingly, the 
free, unconjugated QUE was detected only when QUE was administered in a 
propylene glycol vehicle, in which it was most soluble compared to the other 
vehicles.  They later hypothesized that this phenomenon was likely due to 
animals’ overdosing.  It is not clear whether they meant experimental error 
(animals given more than 50 mg/kg) or a saturation of liver first pass enzymes 
due to more rapid absorption in the vehicle that exhibited the highest solubility.  
Either of these are feasible explanations.  Nonetheless, it was clear that QUE 
was present in vivo mainly as a conjugated metabolite and that its solubility was 
an important factor in overall absorption.  The premise that modulating the 
solubility of QUE could affect its absorption is what fueled our study and others 
before it.  Kim et al (2009) reported several new quercetin-amino acid conjugates 
that exhibited improved water solubility and in vitro stability and permeability 
(Kim, Park et al. 2009).  Even though this will presumably lead to improved 
bioavailability, this remains to be seen due to the lack of an in vivo evaluation.   
In this study, we evaluated the bioavailability of four cocrystals of QUE 
with varying degrees of improved water solubility in comparison to QUE alone.  
Our in vivo pharmacokinetic evaluation is in agreement with existing literature in 
that modulating solubility did impact absorption patterns of the QUE cocrystals.  
Since solubility often limits the rate of absorption of a compound, one would 
expect that improving the solubility of a poorly soluble compound would shift to 
the left the time at which maximal plasma levels were achieved.  This was the 
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case for all of the cocrystals presented in this study.  In table 4.1, the QUE 
dihydrate control had a TMAX of 30 minutes, whereas the cocrystals peaked at 5 
and 10 minutes.  Not only did the QUE cocrystals reach systemic circulation 
more quickly than QUE dihydrate but they also reached significantly higher 
concentrations.  The QUECAF•MeOH cocrystal peaked rapidly at 5 minutes with 
7.7 µM free QUE.  For comparison, the QUE dihydrate control peaked at 30 
minutes with 0.84 µM QUE aglycone.   
Even though solubility is a limiting factor of the oral bioavailability of QUE, 
it is apparent that it is not the only factor.  Modulation of metabolism can also 
have drastic effects on oral bioavailability.  Recently, one study reported that 
several ester-based precursors to QUE might be useful for increasing systemic 
aglycone concentrations (Biasutto, Marotta et al. 2007).  The investigators 
demonstrated that some ester precursors were resistant to phase II conjugation 
by tight monolayers of MDCK-1, MDCK-2, and Caco-2 cells.  They hypothesize 
that in vivo the residual acyl groups will be eliminated leaving the QUE aglycone 
that is known to be bioactive.  Although this data is promising, the study is limited 
due to the lack of in vivo evaluation.  Additionally, one of the major limitations to 
QUE is its very low water solubility.  Each of these precursors was reported to 
exhibit solubility similar to QUE.  This might pose a formulation dilemma due to 
insolubility and poor dissolution at physiologically relevant doses in vivo.   
Interestingly, post-hoc analysis of the pharmacokinetic curve (Fig 4.4) 
revealed that modulation of solubility is probably not the only contributing factor 
to the improved bioavailability of some of the QUE cocrystals.  This is evident 
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when the relative solubilities of each cocrystal (Fig 4.3) are compared to the 
pharmacokinetic profile (Fig 4.4).  Based on solubility differences alone, the 
QUECAF cocrystal would be expected to have the highest CMAX since it would be 
solubilized, and thus absorbed, more completely than the others.  However, the 
QUECAF cocrystal had the lowest CMAX of all of the cocrystals, peaking at just 
656 ng/mL at 10 minutes.  Furthermore, the QUEINM cocrystal had the second 
lowest solubility and caused systemic QUE aglycone levels to reach 1401 ng/mL, 
second only to the QUECAF•MeOH cocrystal.  Therefore, there must be factors 
other than solubility at play.  It is possible that the INM might reduce the first pass 
effect of the liver enzymes on QUE.  Perhaps most interesting is the 
pharmacokinetic profile of the QUETBR•2H2O cocrystal (Fig 4.4).  Despite having 
a solubility that is only slightly higher than QUE dihydrate, this cocrystal achieved 
sustained levels of quercetin aglycone, indicative of modulated elimination.  The 
resultant FREL of the QUETBR•2H2O cocrystal was 9.93, the largest increase 
observed in this study (Table 4.1).  This cocrystal also exhibited the longest E 
T1/2, 145 minutes (Table 4.1).  Still, we cannot reach any definitive conclusion 
about the metabolism of the cocrystals since we did not measure circulating QUE 
metabolites.   
These results add to existing evidence that cocrystallization is a useful 
methodology for improving the physicochemical properties of a compound and 
that these improvements can lead to drastically enhanced bioavailability when 
applied to compounds that are limited by their solubility.  This same ideology was 
previously shown to be successful in several preclinical studies.  Carbamazepine 
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(CBZ) is used for the treatment of epilepsy and bipolar disorder but also suffers 
from low solubility and oral bioavailability.  Cocrystals of CBZ and saccharin were 
administered orally to dogs and were found to achieve greater plasma 
concentrations than the API alone (Hickey, Peterson et al. 2007).  This 
improvement in bioavailability was attributed to the improved solubility of the 
cocrystal.  AMG 517, VR1 (vanilloid receptor 1) antagonist is a practically 
insoluble drug, which limits its bioavailability.  Bak et al reported that the 
cocrystallization of AMG 517 with sorbic acid dramatically increases its 
bioavailability in rats (Bak, Gore et al. 2008).  Similarly, Jung et al used 
cocrystallization to improve the solubility, and consequent bioavailability of 
indomethacin (Jung, Kim et al. 2010).  Thus, modulating the solubility of a poorly 
soluble API using cocrystallization appears to be a proven, highly effective, and 
broadly applicable method for improving oral bioavailability.   
Taken with the existing evidence from the literature, the results of this 
study further implicate the potential for cocrystallization in drug development.  
One limitation is that the plasma samples were analyzed for free, unconjugated 
QUE content alone.  This is because modulated metabolism was not an 
expected outcome of cocrystallization. However, given the unexpected 
discrepancies between the solubility and pharmacokinetic profiles of the 
cocrystals, modulated metabolism is probable.  Future studies should investigate 
whether cocrystallization with certain cocrystal formers can be used to modulate 
the metabolism of the API.  Nevertheless, this study implicates cocrystallization 
as a potential solution to the solubility and bioavailability problems that thwart the 
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success of QUE as an effective treatment option for its numerous clinical 
indications.   
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CHAPTER 5 
 
MODULATING THE SOLUBILITY OF EGCg USING COCRYSTALLIZATION 
AND ITS EFFECTS ON PHARMACOKINETICS 
 
5.1 Introduction 
 EGCg and it’s therapeutic uses, metabolism, and problematic clinical 
translation are discussed in detail in Chapter 1.  Due to extremely poor 
bioavailability, novel methods for improving its absorption and/or therapeutic 
efficacy are desirable.  Nanolipidic particles were used to improve the absorption 
of EGCg in Chapter 3.  This chapter aims to modulate the dissolution, and 
consequent pharmacokinetics of EGCg using cocrystallization.   
 In the previous chapter, modulating the solubility of quercetin using 
cocrystallization drastically improved its bioavailability.  However, unlike 
quercetin, EGCg is highly soluble in water.  Therefore, it was selected to 
determine the effects that reducing the solubility through cocrystallization might 
have on the pharmacokinetic profile.  Compounds that are highly water-soluble 
are typically absorbed well in the gastrointestinal tract but are consequently 
easily excreted and, thus, exhibit low half lives (T1/2).  We hypothesized that we 
could improve the circulation time of EGCg by reducing its water solubility 
through cocrystallization.  This chapter will describe the synthesis, solubility, and 
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bioavailability of four new EGCg cocrystals: EGCg/Nicotinamide hydrate 
(EGCgNIC•9H2O), EGCg/Isonicotinamide hydrate (EGCgINM•5H2O), 
EGCg/Isonicotinic Acid (EGCgINA), EGCg/Isonicotinic Acid hydrate 
(EGCgINA•3H2O).   
5.2 Materials and Methods 
5.2.1 Reagents 
EGCg (>95% purity by HPLC) was purchased from www.herbs-tech.com.  
Isonicotinamide (INM) (99% purity), Nicotinamide (99% purity), and Isonicotinic 
Acid (99% Purity) were purchased from Sigma-Aldrich Corporation (St. Louis, 
MO, USA).   
5.2.2 Synthesis of the cocrystals 
 
Figure 5.1 
EGCg cocrystal reaction scheme.  
Isonico'namide,
H2O,
Isonico'nic,Acid,
Nico'namide,
EGCgINM•5H2O,
,
EGCgINA•3H2O, EGCgINA,
EGCgNIC•9H2O,
,
H2O,
H2O,
85oC,,
EGCg,
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EGCgNIC•9H2O: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and nicotinamide 
(99% pure,12.21 mg, 0.1000 mmol) were dissolved in 2 mL of water.  Colorless 
crystals were harvested after 3 days.  The cocrystal can also be obtained by 
solvent drop grinding and slurrying with water.  (melting point = 90.0 oC). 
EGCgINM•5H2O: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and iso-
nicotinamide (99% pure, 12.21 mg, 0.1000 mmol) were dissolved in 6 mL of 
water. Colorless crystals were harvested after ca. 5 minutes.  (melting point = 
155.0 oC).   
EGCgINA•3H2O: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and isonicotinic acid 
(99% pure, 12.31 mg, 0.1000 mmol) were dissolved in 10 mL of water. Colorless 
crystals were harvested after 1 day. The cocrystal can also be obtained by 
solvent drop grinding and slurrying with water.  (melting point = 190 oC).  
EGCgINA: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and isonicotinic acid (99% 
pure, 12.31 mg, 0.1000 mmol) were dissolved in 10 mL of water. Colorless 
crystals were harvested after 1 day. The cocrystal can also be obtained by 
solvent drop grinding and slurrying with water.  The cocrystal loses water after 
heating, converting to an anhydrous cocrystal.  (melting point = 190 oC). 
5.2.3 Solubility evaluation 
Solubility studies were performed on EGCgNIC•9H2O, EGCgINM•5H2O, 
EGCgINA•3H2O, and EGCgINA.  Each of the cocrystals was synthesized in bulk 
by taking stoichiometric ratios of the starting materials in methanol and slurrying 
them for 24 hours, which produced the cocrystals in 100% yield.  The slurries 
were dried at room temperature and were sieved to attain a particle size between 
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53 and 75 µm.  The solubility study was done by taking approximately 4 grams of 
the cocrystal in 30 mL of water and was stirred with magnetic stir bar at ca. 125 
rmp for 24 hours.  Aliquots were drawn from the slurry and filtered using a 0.45 
µm nylon filters.  The remaining solid was analyzed by PXRD and DSC.  For 
every cocrystal, 1mL of the filtered solution from the slurry was transferred into a 
pre-weighed (w1) vial by using an analytical balance and was put on a hot plate 
(maintained at 50 oC) to evaporate the water.  The vial was weighed again (w2) 
and the difference in the weights (w2-w1) gave the weight of the cocrystal in 1ml 
of water from which the weight of EGCg was calculated. The solubility studies 
and the gravimetric methods were done in replicates of three.  
5.2.4 Pharmacokinetic screening of EGCg formulations in rats 
Male Sprague Dawley rats (n=3 per group) weighing 200-250 g were purchased 
from Harlan Laboratories (Indianapolis, IN).  The rats were purchased pre-
cannulated by Harlan.  The rounded tip catheters were surgically implanted into 
the jugular vein of the rats making multiple, precise blood draws painless to the 
animal.  The rats were food (not water) deprived for 18 hours prior to the start of 
the experiment. Vegetable oil was selected as the gavage vehicle because all 
crystal forms were observed to be insoluble in it.  Crystallographic data was used 
to calculate the equivalent weight of each multiple component cocrystal to 
provide a 100 mg/kg dose of EGCg (Mukherjee, Clarke et al. 2011).  The EGCg 
formulations were delivered via oral gavage at a dosage of 100 mg EGCg/kg 
body weight.  Blood was collected at the following time points: 0, 5, 10, 30, 60, 
120, 240, and 480 minutes.  Because heparin was kept in the catheter lines to 
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prevent clotting, a small amount of blood was drawn and discarded before 
collecting each sample.  Approximately 300 µL of blood was collected in EDTA 
tubes for each time point.  The samples were kept on ice to preserve their 
integrity, then centrifuged at 4000 rpm for 10 minutes, after which the plasma 
was transferred to sterile centrifuge tubes.  A preservative solution was added to 
each plasma sample at 10% (v/v) concentration to ensure the integrity of the 
EGCg during storage (Lambert, Lee et al. 2006).  This preservative was 
comprised of 20% ascorbic acid (to prevent oxidation) and 0.1% EDTA (to 
scavenge any metal contaminants).  The samples were stored at -80°C until they 
were analyzed for EGCg content. 
5.2.5 Quantification of EGCg in rat plasma 
Refer to 2.7.1. 
5.2.6 Statistical analysis 
A post hoc t-test with Bonferroni correction was used to assess the statistical 
significance at each time point for the pharmacokinetic study.  Each EGCg 
cocrystal was compared to the EGCg control.  The criterion for rejection of the 
null hypothesis was P<0.05. 
5.3 Results 
5.3.1 Crystallography 
EGCgNIC•9H2O:  The single crystal x-ray diffraction data revealed that 
EGCgNIC•9H2O is a 2:2 cocrystal of EGCg and nicotinamide with 9 water 
molecules.  The intermolecular hydrogen bonding of the cocrystal is shown in 
Figure 5.2.   
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Figure 5.2 
EGCgNIC•9H2O intermolecular hydrogen bonds. The intermolecular hydrogen 
bonds are indicated by blue dotted lines on the left.  As a hydrate, water 
molecules exist in the crystal structure and are indicated by red balls on the right.  
 
EGCgINM•5H2O:  The single crystal x-ray structure analysis revealed that 
EGCgINM•5H2O is a hydrated, 1:1 cocrystal of EGCg and isonicotinamide. 
EGCg molecules and isonicotinamide molecules interact through single-point 
hydrogen bonds (O-H···N, O···N: 2.756Å) between the hydroxyl group of EGCg 
molecule and the aromatic nitrogen of isonicotinamide molecules.  These dimeric 
units are connected further by O-H···O (O···O: 2.662Å) hydrogen bonds formed 
between the hydroxyl moieties of EGCg and carbonyl moieties of isonicotinamide 
molecules.  This results in the zig-zag chain formation shown in Figure 5.3.  
	  
Figure 5.3 
EGCgINM•5H2O intermolecular hydrogen bonds.  The intermolecular hydrogen 
bonds are indicated by blue dotted lines. 
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EGCgINA•3H2O:  The single crystal x-ray structure analysis revealed that 
EGCgINA•3H2O is a trihydrate co-crystal of EGCG and nicotinamide at a 1:1 
ratio.  The intermolecular hydrogen bonds are illustrated in Figure 5.4. 
 
Figure 5.4 
EGCgINA•3H2O intermolecular hydrogen bonds.  The intermolecular hydrogen 
bonds are indicated by blue dotted lines. 
 
EGCgINA:  It is possible to generate a stable anhydrous form of the 
EGCgINA•3H2O cocrystal by heating to 85°C.  The water loss can be 
confirmed by comparing the differential scanning calorimetry data before 
and after heating (Figure 5.5). 
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Figure 5.5 
Differential scanning calorimetry data of EGCgINA and EGCgINA•3H2O.  The 
first dip in the green line is indicative of water loss for the hydrate.  The first dip is 
nonexistent in the red line because water is not present in this cocrystal.   
 
5.3.2 Solubility of the EGCg cocrystals 
EGCg is considered to have good aqueous solubility (approximately 20 mg/ml).  
We determined the solubility profiles of four new EGCg cocrystals.  All of the 
cocrystals exhibited reduced water solubility.  Figure 5.6 shows the dissolution 
profiles of EGCg and the EGCg cocrystals.  The maximum solubility of EGCg 
determined experimentally was in agreement with published values, 
approximately 22 mg/ml.  The EGCG cocrystals exhibited far lower aqueous 
solubility.  This is apparent in Figures 5.6 and 5.7.  The most soluble cocrystal 
was EGCgNIC•9H2O at 2.95±0.11 mg/ml.  This was followed by EGCgINA, 
EGCgINM•5H2O, and EGCgINA•3H2O at 1.227±0.036, 1.401±0.122, 0.97±0.07, 
respectively.   
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Figure 5.6 
Dissolution profiles of EGCg and EGCg cocrystals in water. 
 
 
Figure 5.7 
Dissolution profiles of EGCg cocrystals alone in water. 
 
5.3.3 Pharmacokinetics of EGCg cocrystals 
The pharmacokinetic curves for EGCg and the EGCg cocrystals are shown in 
figure 5.8.  EGCg exhibited the prototypical pharmacokinetic curve for a highly 
water-soluble small molecule: rapid peak and elimination.  The EGCg cocrystals 
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exhibited very different pharmacokinetic profiles.  The pharmacokinetic 
parameters are shown in Table 5.1.  EGCg peaked rapidly at 5 minutes (Tmax) 
due to its high solubility and, consequent, high rate of dissolution.  The cocrystals 
peaked in the plasma in the following order: EGCgNIC•9H2O, EGCgINM•5H2O, 
EGCgINA•3H2O, EGCgINA.  Surprisingly, only two of the cocrystal forms 
resulted in improved bioavailability: EGCgINA•3H2O and EGCgINA.  These 
cocrystals had modest improvements in relative bioavailability at FREL of 1.53 and 
1.18, respectively.  Free EGCg peaked at higher concentrations and more 
quickly than the cocrystal forms.  However, cocrystallization did change the 
overall shape of the pharmacokinetic curve. In some cases, these 
pharmacokinetic profiles might be advantageous to the typical peak and 
elimination profile of free EGCg.   
 
Figure 5.8 
Pharmacokinetic profiles of EGCg and EGCg cocrystals. 
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Table 5.1. Pharmacokinetic parameters 
 EGCg EGCgNIC•9H2O EGCgINM•5H2O EGCgINA•3H2O EGCgINA 
TMAX 
(min) 5.0 10.0 30.0 60.0 120.0 
CMAX 
(ng/ml) 337.2 185.8 126.0 297.9 149.6 
AUC 35602.0 25237.0 22707.0 54560.0 41937.0 
FREL 1.00 0.71 0.64 1.53 1.18 
A T1/2 
(min) 1.64 3.75 10.44 30.53 62.71 
 
5.4 Discussion and conclusions 
 Tea is the most widely consumed beverage in the world.  One of the most 
popular types of tea is green tea.  Green tea contains numerous bioactive 
ingredients but the most beneficial class of compounds is thought to be the 
polyphenols.  Of the polyphenols found in green tea, EGCg is the most abundant.  
EGCg research increased drastically when researchers reported that 
epidemiological evidence indicated lower rates of certain cancers in populations 
that consumed the most green tea.  Since then, numerous molecular 
mechanisms for these beneficial properties have been discovered.  Not 
surprisingly, EGCg has become one of the most popular nutraceutical ingredients 
in the world.  However, reports of its poor bioavailability are troublesome to 
product development (Landis-Piwowar, Huo et al. 2007; Dube, Nicolazzo et al. 
2010; Kale, Gawande et al. 2010; Smith, Giunta et al. 2010).  EGCg is highly 
susceptible to oxidation, first pass metabolism and rapid efflux (Kale, Gawande 
et al. 2010).  Numerous groups have evaluated delivery systems to overcome 
these limitations but none have tried cocrystallization.   
 In this study, we report four new cocrystals of EGCg all with reduced water 
solubility.  We hypothesized that these changes in solubility would change the 
pharmacokinetics of EGCg, perhaps improving it’s bioavailability.  At first glance, 
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it seems that cocrystallization might not be the most useful method for improving 
the bioavailability of EGCg, since only two cocrystals exhibited improved 
bioavailability and the increases were very modest (Table 5.1).  However, that 
does not mean that cocrystallization cannot benefit the commercialization of 
EGCg.  The ability to have multiple solid forms of EGCg with different 
physicochemical properties and pharmacokinetic profiles could be very useful.  
Further examination of Figure 5.8 indicates that some of the EGCg cocrystals 
exhibited very unique pharmacokinetic profiles.  The EGCgINA•3H2O and 
EGCgINA cocrystals not only had the highest relative bioavailabilities, but also 
resulted in higher concentrations of free EGCg after 60 and 120 minutes.  This 
plateau effect could be useful for achieving more sustained levels of EGCg in the 
blood.  Additionally, because nutraceutical products often contain combinations 
of ingredients with synergistic effects, cocrystallization could be used to select 
forms with similar pharmacokinetic curves as the other ingredients, thus, 
optimizing the synergisms.   
 Our results generally had the hypothesized effect: reducing the solubility 
reduced the rate of dissolution and delayed the time at which maximal plasma 
levels were reached (Tmax).  EGCgNIC•9H2O was the most water-soluble 
cocrystal form and had the most rapid Tmax after free EGCg.  EGCgINM•5H2O 
and EGCgINA•3H2O had expected Tmax values as well.  However, EGCgINA 
peaked last at 120 minutes (Table 5.1) and was the second most soluble 
cocrystal (Figure 5.7).  This phenomenon cannot be explained by our solubility 
hypothesis.  Normally, it might be reasonable to assume that perhaps other 
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pharmacokinetic parameters are being changed, like elimination rate or 
metabolism.  However, this would normally be attributed to some effect of the 
cocrystal former.  This theory is debunked in our experiment because we 
evaluated EGCgINA and EGCgINA•3H2O.  As expected, the hydrate exhibited 
lower water solubility and peaked later in comparison to the other more soluble 
EGCg forms.  Because anhydrous and hydrous forms were evaluated, we are 
able to conclude that the presence of isonicotinic acid does not explain the 
discrepancy observed with the EGCgINA cocrystal.  This phenomenon could be 
due to experimental error since this was a relatively low n study.   
 In conclusion, cocrystallization might not be the best option for improving 
the bioavailability of highly water-soluble cocrystals.  However, it could be very 
useful when absorption kinetics is critical such as it is in synergistic combination 
products.  Additionally, cocrystallization is capable of broadening intellectual 
property since the only requirement for cocrystal formation is complementary 
functional groups.  This is unlike salts, which require the presence of ionizable 
species severely limiting the number of possibilities and, in many cases, 
rendering the potential for salt formation impossible for certain compounds.  This 
study is good proof of principle for the use of cocrystallization to modulate the 
pharmacokinetics of highly water-soluble compounds.  In this study, we 
described the creation of four new solid forms of EGCg, each with unique 
physicochemical properties and pharmacokinetic characteristics.  
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CHAPTER 6 
 
DISCUSSION 
 
6.1 Nanolipidic flavonoid complexes 
 Nanoparticles have been long studied as a means of preformulation for 
improving the oral bioavailability of various compounds.  Most often, the 
compounds selected for nanoparticle preformulations exhibit low water solubility 
and, thus, dissolve slowly or incompletely thwarting their absorption and 
bioavailability.  These compounds generally fall under the Biopharmaceutics 
Classification System (BCS) as Class II active pharmaceutical ingredients 
because they present low solubility and high permeability.  BCS Class II 
compounds are generally limited by their rate of dissolution, which slows their 
absorption.  Recently, one group has utilized solid lipid nanoparticles to 
drastically improve the bioavailability of another natural compound, curcumin 
(Kakkar, Singh et al. 2011).  Curcumin has very poor bioavailability due to 
inadequate water solubility.  Kakkar et al reported increases in oral bioavailability 
of up to 155 times, dependent on the dose administered.   
 Nanolipidic particles have been reported to increase the absorption of 
compounds via the lymphatic system (Porter, Trevaskis et al. 2007).  Lymphatic 
drug absorption requires a compound to be highly lipophilic or to be complexed 
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to a lipidic material as is the case with nanolipidic particles.  Lymphatic 
absorption offers the advantage of bypassing first pass metabolism, resulting in 
elevated systemic circulation levels of the free xenobiotic.  These were key 
factors that contributed to our development of EGCg nanolipidic particles and 
provided rationale for our pharmacokinetic studies.  We evaluated the 
pharmacokinetics of nanolipidic EGCg particles using Sprague dawley rats.  We 
administered the “free” EGCg in the same vehicle that was used in the 
NanoEGCg formulation minus the lipid carrier.  What we found was that EGCg 
was absorbed very poorly, peaking at 116 ng/ml.  In comparison, the NanoEGCg 
formulations exhibited more than double the relative bioavailability.  Given that 
lipidic formulations have been shown to increase lymphatic absorption (Peng, 
Zhang et al. 2010), it is possible that this is one mechanism for the improved 
bioavailability of NanoEGCg.  Additionally, EGCg has been shown to be highly 
susceptible to metabolism in the gastrointestinal tract pre-absorption (Takagaki 
and Nanjo 2010), thus, it is possible that the NanoEGCg is less susceptible 
metabolism by intestinal flora.  Unfortunately, one major limitation to this 
technology is that it requires ethanol for nanoparticle formation.  This is not ideal 
for the commercialization of EGCg as a dietary supplement or as a drug.  Not 
only this, but the ethanol content alone probably effected the absorption of 
EGCg.  This is evidenced by the fact that the plasma levels reached by our 
EGCg control were lower than previously reported (Lin, Wang et al. 2007).  This 
limitation must be considered when interpreting the results but does not change 
the fact that the systemic absorption of free EGCg in the nanoEGCg formulation 
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was vastly superior to the control.  Alternative methods for nanoEGCg production 
without alcohol should be explored in future studies.   
6.2 Solid-state chemistry 
 The fact that the majority of drugs are marketed and sold as solid dosage 
forms is a testament to the importance of solid-state chemistry in the 
pharmaceutical industry.  They have important implications in clinical, legal, and 
even regulatory perspectives.  Perhaps the most pertinent factor contributing to 
the emphasis being placed on solid-state chemistry is the fact that novel solid 
forms offer a way to change the physicochemical characteristics of compounds 
with less than desirable properties in their pure form.  One of the most rapidly 
emerging new solid forms are cocrystals.  Shan and Zaworotko have defined 
cocrystals as “multiple component crystals in which all components are solid 
under ambient conditions.  These components co-exist as a stoichiometric ratio 
of a target molecule or ion and a neutral molecular cocrystal former(s)” (Shan 
and Zaworotko 2008).  Cocrystals are particularly useful because they involve 
noncovalent hydrogen bonds, which pose fewer limitations than covalent 
modifications and ionic complexes (salts).  Because cocrystals can be formed 
from compounds without ionizable species, the number of possible combinations 
are staggering in comparison to other solid forms.   
 Recent advances in crystal engineering have propelled cocrystallization to 
the forefront of solid-state chemistry.  Now, supramolecular heterosynthons that 
seem to favor the formation of cocrystals have been discovered.  Those relevant 
to the studies discussed in chapters 4 and 5 are exemplified by carboxylic acid-
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aromatic nitrogen, carboxylic acid-amide, and alcohol-pyridine (Shan and 
Zaworotko 2008).  This supramolecular synthon approach was employed in the 
development of all of the cocrystals evaluated in this report.  This took much of 
the trial and error out of cocrystal development and allowed for effective selection 
of cocrystal formers that were most likely to hydrogen bond with the 
bioflavonoids: EGCg and quercetin.  Furthermore, these synthons can be applied 
to other structurally similar bioflavonoids.  The studies described in previous 
chapters of this report attest to the effectiveness of this crystal engineering 
approach.   
6.2.1 Pharmacokinetic implications of cocrystals of quercetin 
 Quercetin was chosen as one of the bioflavonoids for these 
cocrystallization studies because it exhibits extremely low water solubility, a very 
common problem in drug development.  Quercetin’s water solubility of 0.00215 
mg/mL (Srinivas, King et al. 2010) is the major contributor to it’s poor 
bioavailability.  For a compound to be absorbed by the body it must dissolve, 
which is dependent on it’s solubility in aqueous mediums.  Our hypothesis was 
that we could improve the solubility of quercetin by forming new cocrystal forms.  
In turn, this would produce predictable changes in the pharmacokinetic profiles 
leading to improvements in the bioavailability.   
 Our results supported this hypothesis in a broad sense.  Each of the four 
cocrystals exhibited marked improvements in solubility.  However, our ability to 
evaluate the changes in pharmacokinetics that could be produced by small 
differences in aqueous solubility was limited because we were forced to use a 
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50% ethanol medium to produce quantifiable levels of quercetin for the quercetin 
dihydrate control.  Although this makes it difficult to make accurate conclusions 
that are physiologically relevant, it is very obvious that the cocrystals exhibited 
increased solubility and improved bioavailability.  Additionally, we would expect 
that increasing the solubility would increase the rate of dissolution and cause the 
plasma levels to peak earlier.  This was the case for all of the quercetin cocrystal 
formulations.  The quercetin dihydrate control was absorbed slowly (Tmax at 30 
minutes) and poorly (Cmax at 285 ng/mL).  In comparison, the quercetin 
cocrystals reached peak levels at 5 and 10 minutes.  The QUECAF•MeOH 
peaked the highest at 2612 ng/mL followed by QUEINM at 1401 ng/mL, 
QUETBR•2H2O at 840 ng/mL, and QUECAF at 656 ng/mL.  This increases in 
absorption resulted in increases in bioavailability of up to nearly 10 fold.  The 
lowest performing cocrystal in terms of bioavailability was QUECAF, which still 
produced increases in relative bioavailability of 2.57 fold.  The cocrystals were 
absorbed similarly and there was little meaningful difference in the absorption 
half lives.  However, the elimination half lives were indicative of major changes in 
the pharmacokinetics of the cocrystals.  This was unexpected.  We anticipated 
that we would change the rate of dissolution, improving the absorptive phase of 
the cocrystals.  However, it appears that cocrystallization also produces profound 
effects on the elimination phase.  This was most evident for QUETBR•2H2O that 
exhibited an elimination half life of 145 minutes.  This parameter can be 
visualized by looking the shape of the pharmacokinetic curve (Figure 4.4).  The 
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shape is not a peak with rapid elimination, but a peak with a plateau effect.  This 
is what produced huge gains in bioavailability (FREL=9.93).   
 The impact of these studies is two fold.  It provides more evidence that 
poorly soluble compounds can be improved drastically using cocrystallization 
(Hickey, Peterson et al. 2007; Bak, Gore et al. 2008; Jung, Kim et al. 2010).  
Also, it could help commercialize quercetin as a dietary supplement and 
eventually as a therapeutic agent.  QUE is best known for its antioxidant activity 
but has numerous other biological and pharmacological effects including metal 
chelation, anti-carcinogenic, cardioprotective, bacteriostatic, and antiviral activity 
(Vargas and Burd ; Bakay, Mucsi et al. 1968; Formica and Regelson 1995; 
Spencer, Kuhnle et al. 2003; Leopoldini, Russo et al. 2006; Murakami, Ashida et 
al. 2008).  However, these bioactivites are meaningless unless it’s poor 
absorption and bioavailability can be overcome.  Our studies offer four quercetin 
cocrystals that accomplish this.  Future studies will need to assess the translation 
of these results into humans.   
6.2.2 Pharmacokinetic implications of cocrystals of EGCg 
 EGCg was selected for this study to represent the opposite end of the 
solubility spectrum.  EGCg is a highly water-soluble compound.  We used the 
supramolecular heterosynthon approach to identify cocrystal formers with 
complementary functional groups to form hydrogen bonds with the hydroxyl 
groups abundant on EGCg.  This crystal engineering approach to cocrystal 
design was very effective and we generated several new EGCg cocrystals.  The 
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four presented in this study were selected to advance to the in vivo 
pharmacokinetic studies.   
 EGCg usually exhibits a prototypical pharmacokinetic profile for highly 
water soluble compounds: it peaks rapidly and is eliminated rapidly from 
systemic circulation via tissue distribution and metabolism at the liver.  We 
hypothesized that cocrystals with reduced solubility would change the dissolution 
and consequent absorption of the compound in the gastrointestinal tract.  This 
hypothesis was mostly supported by our results.   
 We evaluated four new cocrystal forms of EGCg in a rat model of 
pharmacokinetics and bioavailability.  The EGCg formulations were administered 
in vegetable oil to prevent presolubilization of the powder forms.  Sieving the 
powders prior to slurrying in vegetable oil and dosing the animals via oral gavage 
regulated the particle size.  The EGCg control was absorbed rapidly absorbed 
(TMAX=5 minutes) and eliminated quickly.  The EGCg cocrystals exhibited a 
delayed absorption pattern that coincided with the decreases in solubility in all 
cases except one: EGCgINA.  This cocrystal was the second most soluble but 
appeared in the plasma last.  We can only attribute this to experimental error 
since there is no other explanation for it.  That aside, our hypothesis was 
supported by our results.  Interestingly, oral bioavailability was not improved from 
EGCg alone except very modestly with the EGCgINA•3H2O and EGCgINA 
cocrystals.  These cocrystals had the latest TMAX values.   
 Although, at first glance, it might be easy to conclude that cocrystallization 
is not useful for improving the bioavailability of highly water-soluble compounds 
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this might not be true.  In this study, we generated four new cocrystal forms of 
EGCg with different physicochemical and pharmacokinetic properties.  During 
commercialization, it is possible to formulate the EGCg cocrystals into a 
combination product.  This, in theory, has the potential to create sustained 
plasma levels of free EGCg.  This possibility was simulated in Figure 6.1. 
 
Figure 6.1 
Pharmacokinetic curve of theoretical combination delivery of all cocrystal forms 
simultaneously (25 mg/kg each). 
 
Figure 6.1 was generated by combining the experimental pharmacokinetic curves 
of all of the cocrystals divided by 4 (to adjust the dose to 100 mg/kg total of 
EGCg).  In theory, this is the pharmacokinetic curve that would occur if all of the 
cocrystal forms were dosed into an animal at once.  As shown in Figure 6.1, this 
would cause the pharmacokinetic curve to plateau similar to other sustained 
release preformulation techniques like transdermal delivery.  Sustained plasma 
levels are preferred so that the therapeutic bioactivity of the active ingredient is 
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maintained for a longer duration.  Even though transdermal delivery can also 
accomplish sustained plasma levels, it has numerous disadvantages to oral 
formulation such as complicated production, increased cost, and reduced patient 
compliance due to common side effects like skin irritation at the adhesion site. 
 A single cocrystal with reduced solubility from the pure form of a highly 
water-soluble compound is unlikely to produce improved bioavailability.  
However, the ability to modulate the pharmacokinetic curve could be very useful 
in the clinical translation of active ingredients.  The opportunities are there to 
create combination products that produce sustained plasma levels of a single 
active ingredient.    
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APPENDIX 1: 
 
 
ADDITIONAL QUERCETIN COCRYSTAL FIGURES 
 
 
 
 
 
 
 
IR DSC 
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PXRD (Experimental and Calculated) 
Figure A1.1 
QUECAF•MeOH (Methanol solvate of 1:1 cocrystal Quercetin and Caffeine) 
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IR DSC 
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PXRD (Experimental and Calculated) 
 
Figure A1.2 
QUECAF (1:1 cocrystal Quercetin and Caffeine) 
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IR DSC 
 
 
 
PXRD (Experimental and Calculated) 
Figure A1.3 
QUEINM (1:1 cocrystal of Quercetin and Isonicotinamide) 
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IR DSC 
 
 
 
PXRD (Experimental and Calculated) 
Figure A1.4 
QUETBR.2H2O (Dihydrate of 1:1 cocrystal of Quercetin and Theobromine) 
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APPENDIX 2: 
 
DATA SHEET FOR EGCGNIC•9H2O: HYDRATE OF 1:1 COCRYSTAL OF 
EPIGALLOCATECHIN GALLATE (EGCG) AND NICOTINAMIDE 
 
 
Description: 
The single crystal x-ray structure analysis reveals that EGCGNIC•9H2O is a 
decahydrate of 2:2 co-crystal of EGCG and nicotinamide.  
 
Figure A2.1: FT-IR of EGCGNIC•9H2O. (Nicolet Avatar 320 FTIR, solid state) 
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Figure A2.2: DSC of EGCGNIC•9H2O (TA instrument 2920) 
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Figure A2.3: Powder x-ray diffraction patterns of EGCGNIC•9H2O  
Calculated (top) and Experimental (bottom)  
(Bruker AXS D8, Cu radiation) 
 
 
Major peaks were observed in the experimental PXRD pattern at the following 
positions: 8.8, 11.9, 13.3, 15.8, 17.2, 18.4, 19.3, 20.3, 21.2, 23.5, 24.2, 25.1, 
26.1, 27.7, 28.8, 29.7, 33.0 and 34.4 degrees. 
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Figure A2.4: Comparison of powder x-ray diffraction patterns of 
EGCGNIC•9H2O.  
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Major peaks were observed in the experimental PXRD pattern at the following 
positions: 8.8, 11.9, 13.3, 15.8, 17.2, 18.4, 19.3, 20.3, 21.2, 23.5, 24.2, 25.1, 
26.1, 27.7, 28.8, 29.7, 33.0 and 34.4 degrees. 
 
 
Figure A2.5: TGA analysis of EGCGNIC•9H2O 
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Table A2.1: Single crystal x-ray diffraction data for EGCGNIC•9H2O 
(Bruker-AXS SMART APEX CCD diffractometer) 
 
Crystallographic data 
Identification code  EGCgNIC•9H2O 
Empirical formula  2(C22 H18 O11) · 2(C6 H6 N2 O) · 10(O)   
Formula weight  660.49 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 10.497(2) Å a= 72.56(3)°. 
 b = 11.769(2) Å b= 85.80(3)°. 
 c = 12.203(2) Å g = 83.00(3)°. 
Volume 1426.4(5) Å3 
Z 2 
Density (calculated) 1.538 Mg/m3 
Absorption coefficient 1.128 mm-1 
 
Independent reflections 7923 [R(int) = 0.0411] 
Final R indices [I>2sigma(I)] R1 = 0.0700, wR2 = 0.1904 
R indices (all data) R1 = 0.0832, wR2 = 0.2045 
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Figure A2.6: Digital microscope image of  EGCGNIC•9H2O crystals 
 
 
Figure A2.7: Intermolecular hydrogen bonding in EGCGNIC•9H2O 
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APPENDIX 3: 
 
DATA SHEET FOR EGCGINM•5H2O: HYDRATE OF 1:1 COCRYSTAL OF 
EPIGALLOCATECHIN GALLATE (EGCG) AND ISO-NICOTINAMIDE 
 
 
Description: 
The single crystal x-ray structure analysis reveals that EGCGINM•5H2O is a 
hydrate of 1:1 cocrystal of EGCG and iso-nicotinamide. EGCG molecules and 
iso-nicotinamide molecules interact through one point hydrogen bonds (O-
H···N, O···N: 2.756Å) between the hydroxyl group of EgCG molecule and the 
aromatic nitrogen of iso-nicotinamide molecules. These dimeric units are 
further connected by O-H···O (O···O: 2.662Å) hydrogen bonds formed between 
hydroxyl moieties of EgCG and carbonyl moieties of iso-nicotinamide 
molecules and thereby form zig-zag chains.  
 
 
Figure A3.1: FT-IR of EGCGINM•5H2O (Nicolet Avatar 320 FTIR, solid state) 
 
 
 
 
 
 
	   	  106	  
Figure A3.2: DSC of EGCGINM•5H2O (TA instrument 2920) 
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Figure A3.3: Calculated (top) and experimental (bottom) powder x-ray 
diffraction patterns of EGCGINM•5H2O (Bruker AXS D8, Cu radiation) 
 
 
Major peaks were observed in the experimental powder x-ray diffraction 
pattern at about the following positions: 7.6, 8.5, 9.2, 11.5, 12.6, 15.4, 18.7, 
19.1, 20.0, 24.7, 26.4, 27.7 and 35.2 degrees. 
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Figure A3.4: Comparison of experimental and calculated powder x-ray 
diffraction patterns of EGCGINM•5H2O 
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Table A3.1: Single crystal x-ray diffraction data for EGCGINM•5H2O  
(Bruker-AXS SMART APEX CCD diffractometer) 
 
Crystallographic data 
 
Empirical formula  C28 H24 N2 O17 
Formula weight  660.49 
Temperature  298(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2 
Unit cell dimensions a = 19.603(8) Å a= 90°. 
 b = 14.491(6) Å b= 92.089(7)°. 
 c = 10.585(4) Å g = 90°. 
Volume 3005(2) Å3 
Z 4 
Density (calculated) 1.460 Mg/m3 
Absorption coefficient 0.124 mm-1 
Independent reflections 4761 [R(int) = 0.0238] 
Final R indices [I>2sigma(I)] R1 = 0.0671, wR2 = 0.1782 
R indices (all data) R1 = 0.0964, wR2 = 0.2235 
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Figure A3.5: Digital microscope image of  EGCGINM•5H2O crystals 
 
Figure A3.6: Intermolecular hydrogen bonding in EGCGINM•5H2O  
 
 
Figure A3.7: An EGCG molecule as it exists in EGCGINM•5H2O 
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APPENDIX 4: 
 
DATA SHEET FOR EGCGINA•3H2O: HYDRATE OF 1:1 COCRYSTAL OF 
EPIGALLOCATECHIN GALLATE (EGCG) AND ISONICOTINIC ACID AND 
EGCGINA: ANHYDRATE OF 1:1 COCRYSTAL OF EPIGALLOCATECHIN 
GALLATE (EGCG) AND ISONICOTINIC ACID 
 
 
Description: 
The single crystal x-ray structure analysis reveals that EGCGINA•3H2O is a 
trihydrate of 1:1 co-crystal of EGCG and nicotinamide.  
 
Figure A4.1: FT-IR of EGCgINA. (Nicolet Avatar 320 FTIR, solid state) 
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Figure A4.2: DSC of EGCGINA•3H2O and EGCgINA (TA instrument 2920) 
 
 
Green = EGCG:Isonicotinic acid trihydrate = EGCGINA•3H2O 
Red = EGCG:Isonicotinic acid anhydrate = EGCgINA 
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Figure A4.3: Powder x-ray diffraction patterns of EGCGINA•3H2O  
Calculated (top) and Experimental (bottom)  
(Bruker AXS D8, Cu radiation) 
 
 
Major peaks were observed in the experimental PXRD pattern at the following 
positions: 12.3, 13.8, 15.2, 18.3, 18.8, 20.6, 21.5, 24.2, 24.8, 25.5, 26.5, 27.6, 
28.1, 29.0, 30.6, 31.5, 32.7, 35.6 and 38.4 degrees. 
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Figure A4.4: Comparison of powder x-ray diffraction patterns of 
EGCGINA•3H2O.  
 
Major peaks were observed in the experimental PXRD pattern at the following 
positions: 12.3, 13.8, 15.2, 18.3, 18.8, 20.6, 21.5, 24.2, 24.8, 25.5, 26.5, 27.6, 
28.1, 29.0, 30.6, 31.5, 32.7, 35.6 and 38.4 degrees. 
 
Figure A4.5: Experimental powder x-ray diffraction patterns of EGCgINA  
 (Bruker AXS D8, Cu radiation) 
 
 
Major peaks were observed in the experimental PXRD pattern at the following 
positions: 6.9, 13.7, 14.5, 17.3, 18.4, 19.3, 20.5, 23.8, 24.7, 27.3, 28.1, 29.9, 
30.6, 34.3, 36.5 and 38.3 degrees. 
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Figure A4.6: Comparison of powder x-ray diffraction patterns of 
EGCGINA•3H2O and EGCgINA. 
 
Major peaks were observed in the experimental PXRD pattern of EGCgINA at 
the following positions: 6.9, 13.7, 14.5, 17.3, 18.4, 19.3, 20.5, 23.8, 24.7, 27.3, 
28.1, 29.9, 30.6, 34.3, 36.5 and 38.3 degrees. 
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Figure A4.7: Comparison of powder x-ray diffraction patterns of EGCgINA, 
EGCG form-1 and isonicotinic acid 
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Major peaks were observed in the experimental PXRD pattern of EGCgINA at 
the following positions: 6.9, 13.7, 14.5, 17.3, 18.4, 19.3, 20.5, 23.8, 24.7, 27.3, 
28.1, 29.9, 30.6, 34.3, 36.5 and 38.3 degrees. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	  117	  
 
Figure A4.8: TGA analysis of EGCGINA•3H2O 
 
 
 
Calculated = 8.5% weight loss for 3 water molecules 
 
Experimental = 6.9% weight loss 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	  118	  
Table A4.1: Single crystal x-ray diffraction data for EGCGINA•3H2O 
(Bruker-AXS SMART APEX CCD diffractometer) 
 
Crystallographic data 
Identification code  EGCgINA•3H2O 
Empirical formula  C22 H18 O11:C6H5NO2:3O 
Formula weight  547.88 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 7.5176(7) Å a= 90°. 
 b = 14.0259(11) Å b= 90°. 
 c = 26.174(2) Å g = 90°. 
Volume 2759.9(4) Å3 
Z 4 
Density (calculated) 1.319 Mg/m3 
Absorption coefficient 0.940 mm-1 
 
Independent reflections 4298 [R(int) = 0.0517] 
Final R indices [I>2sigma(I)] R1 = 0.1099, wR2 = 0.2850 
R indices (all data) R1 = 0.1255, wR2 = 0.2959 
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Table A4.2: Single crystal x-ray diffraction data for EGCgINA – unit cell 
parameters 
(Bruker-AXS SMART APEX CCD diffractometer) 
 
Crystallographic data 
Identification code  EGCgINA 
Empirical formula  C22 H18 O11:C6H5NO2 
Formula weight  547.88 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 7.3367(22) Å a= 90°. 
 b = 13.1192(39) Å b= 90°. 
 c = 25.9406(77) Å g = 90°. 
Volume 2496.83 Å3 
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Figure A4.9: Intermolecular hydrogen bonding in EGCGINA•3H2O 
 
 
 
 
 
 
